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Abstract 
Previously, pharmacological activation of Wnt-signaling in human bone marrow-derived 
multipotent stromal cells (hMSC) generated conditioned media (CM) that promoted β-cell 
regeneration in streptozotocin-treated mice. Ductal-derived endocrine progenitors, which have 
been shown to generate β-cells following pancreatic injury, represent a candidate for the ‘signal-
receiving cell’. Ductal (CK19+) cells from mice pancreata obtained by purification of live 
Dolichos Biflorus Agglutinin lectin+ cells and cultured in minimal media supplemented with 
Untreated, Wnt-activated, or Wnt-inhibited CM demonstrated a significantly increased proportion 
of EdU+/CK19+ cells following 48-hours of supplementation but no endocrine phenotype 
acquisition. Lineage-tracing CK19-CreERT;Ai9(RCL-tdT) mice treated with tamoxifen (single 
dose) demonstrated specific labeling of pancreatic CK19+ cells. Streptozotocin treatment (60 
mg/kg/day, 5 days) resulted in decreased β-cell mass, islet density, and insulin+ cell frequency, as 
well as impaired glucose tolerance and increased pancreatic leukocyte infiltration. This model will 
be used in future studies to lineage-trace CK19+ cell contribution during hMSC CM-induced islet 
regeneration. 
 
Keywords: Multipotent Stromal Cell, Conditioned Media, Cell-free Therapy, Islet Regeneration, 
Diabetes, Cytokeratin 19, Ductal Cell, Lineage Tracing, Streptozotocin. 
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Summary 
Type 1 diabetes is characterized by the destruction of insulin-producing β-cells in pancreatic islets, 
leaving patients unable to control their blood glucose. Regeneration of lost β-cells represents a 
promising treatment strategy. Our lab pioneered the use of transplanted human bone-marrow 
derived mesenchymal stem cells (MSC) to stimulate islet regeneration in mice with β-cell 
destruction. Pharmacological activation of the Wnt-pathway in MSC cultures generated a 
concentrated protein mixture (CM) that consistently reduced blood glucose levels in mice with 
diabetes. However, the identity of signal-receiving cells that mediate islet regeneration within the 
pancreas remains unknown. Recently, regeneration of β-cells from pancreatic duct cells has been 
demonstrated. Treating isolated pancreatic duct cells with MSC CM increased their replication 
compared to minimal culture conditions but did not stimulate expression of other pancreatic cell 
proteins. We also characterized a specialized mouse model designed to follow the fate of duct 
cells. This model will be used in future studies to investigate ductal cell contribution to islet 
regeneration following CM injection. These studies contribute to the development of ‘cell-free’ 
regenerative medicine therapies for diabetes. 
 
 
 
 
 
 
 
 
 
 
iv 
 
Co-Authorship Statement 
The following contains material from a manuscript in preparation co-authored by Brianna 
Ananthan, Gillian Bell, Dr. Tyler Cooper, and Dr. David Hess. Brianna Ananthan performed all 
experimental work presented in this thesis in the lab of Dr. David Hess. Gillian Bell helped with 
animal care, experimental conceptualization, and technique training. Dr. Tyler Cooper assisted 
with experimental conceptualization. Dr. David Hess contributed to the design and interpretation 
of all experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Acknowledgements 
 
Firstly, I would like to express my deep appreciation for my supervisor, Dr. David Hess, 
for fostering a supportive lab environment and teaching me a multitude of valuable academic and 
life skills. From my start in the lab as a fourth-year student, your guidance and encouragement 
have increased my passion for science and research as a learner, collaborator, and community 
member. Thank you for your ongoing support and patience through the challenges and 
breakthroughs. The skills developed and lessons learned under your supervision will be ones that 
will stick with me for a lifetime. 
I would like to thank the members of my advisory committee: Dr. Samuel Asfaha, Dr. 
Cheryle Séguin, and Dr. Lina Dagnino for your insight and technical expertise which helped 
advance my project every step of the way. 
Thank you, Gillian Bell, for teaching me so many techniques from cell culture to animal 
care from the beginning. Your expertise and support were instrumental in my path as a graduate 
student. Your willingness to lend a helping hand at every step has been so inspirational. 
I would like to thank all of the members of the Hess lab who provided insight and support 
throughout my thesis work, including Sarah Krause, Yehia Moharrem, Christopher Leclerc, Fiona 
Serack, and Dr. Tyler Cooper. I would also like to thank Sarah and Yehia for the many caffeine 
runs which helped me push through long days. Thank you to Kristin Chadwick at the London 
Regional Flow Cytometry Facility for her services in cell sorting and flow cytometry 
troubleshooting. 
I would also like to thank Canadian Institutes of Health Research and the Juvenile Diabetes 
Research Foundation for providing funding for my work as a graduate student. 
Finally, I would like to thank my family for their wisdom and emotional support throughout 
these two years. To my siblings, Jason, Meghan, Joshua, and Matthew, thank you for always 
listening and providing perspective through the ups and downs. To my partner, Jason, thank you 
for riding this rollercoaster with me with a big heart and open arms. To my parents, I cannot even 
begin to express my appreciation for the unconditional support you’ve given me over the years in 
all of my pursuits. I love you all. 
 
 
 
vi 
 
Table of Contents 
Abstract ............................................................................................................................................ii 
Summary ......................................................................................................................................... iii 
Co-Authorship Statement................................................................................................................ iv 
Acknowledgements .......................................................................................................................... v 
Table of Contents ............................................................................................................................ vi 
List of Figures ............................................................................................................................... viii 
List of Abbreviations ....................................................................................................................... x 
1.0 Introduction .......................................................................................................................... 1 
1.1 Functions of the Pancreas ..................................................................................................... 2 
1.1.1 Human Pancreas Development ...................................................................................... 2 
1.1.2 Glucose Homeostasis and Regulation of Insulin Secretion ........................................... 4 
1.2 Diabetes Mellitus .................................................................................................................. 5 
1.2.1 Type 1 Diabetes ............................................................................................................. 5 
1.2.2 Type 2 Diabetes ............................................................................................................. 6 
1.2.3 Animal Models to Study Diabetes ................................................................................. 9 
1.3 Therapeutic Approaches to Treat Diabetes Mellitus .......................................................... 11 
1.3.1 Drug Treatments .......................................................................................................... 11 
1.3.2 Gene Therapy ............................................................................................................... 12 
1.3.3 Cell Replacement Strategies ........................................................................................ 13 
1.3.4 Endogenous Regeneration of β-cells ........................................................................... 14 
1.4 Multipotent Stromal Cells ................................................................................................... 16 
1.4.1 Properties and Characterization ................................................................................... 16 
1.4.2 MSC-Mediated Repair ................................................................................................. 17 
1.4.3 MSC as a Therapeutic Option for Diabetes ................................................................. 18 
1.4.4 Elucidating the Islet Regenerative Cascade Induced by hMSC CM ........................... 21 
1.5 Hypothesis and Objectives .............................................................................................. 24 
2.0 Cytokeratin 19-expressing cells as a potential target for islet regeneration ......................... 25 
2.1 Introduction ........................................................................................................................ 26 
2.2 Methods .............................................................................................................................. 29 
2.2.1 Assessing pancreatic phenotypic changes in STZ-treated Non-Obese Diabetic/Severe 
Combined Immunodeficient (NOD/SCID) mice .................................................................... 29 
2.2.2 Validating the effects of CHIR99021 and IWR-1 on intracellular β-catenin in hMSC .. 29 
2.2.3 Generating hMSC CM .................................................................................................. 30 
2.2.4 Murine ductal cell culture and hMSC CM supplementation ....................................... 30 
vii 
 
2.2.5 Optimization of STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice ............................ 32 
2.2.6 Islet size, number, and β-cell mass quantification ...................................................... 32 
2.2.7 Glucose tolerance test ................................................................................................. 32 
2.2.8 Assessing pancreatic phenotypic changes in STZ-treated CK19-CreERT;Ai9(RCL-tdT) 
mice ....................................................................................................................................... 33 
2.2.8 Statistical Analysis ........................................................................................................ 33 
2.3 Results ................................................................................................................................. 34 
2.3.1 STZ treatment induced systemic hyperglycemia and increased the frequency of DBA 
lectin+ cells within the pancreas........................................................................................... 34 
2.3.2 STZ treatment increased the proportion of F4/80+ cells within CD45+ and CK19+ cells 
within the pancreas .............................................................................................................. 37 
2.3.3 Treatment of hMSC with CHIR99021 increased intracellular β-catenin and did not 
affect cell survival ................................................................................................................. 40 
2.3.4 Treatment of hMSC with IWR-1 did not affect intracellular β-catenin or cell survival 40 
2.3.5 hMSC CM stimulated proliferation of CK19+ cells in vitro .......................................... 45 
2.3.6 Epithelial-to-mesenchymal transition and endocrine phenotype acquisition were not 
observed in DBA lectin+ cells exposed to hMSC CM in vitro ................................................ 46 
2.3.7 STZ Treatment (60 mg/kg/day x 5 days) induced hyperglycemia in CK19-
CreERT;Ai9(RCL-tdT) mice ..................................................................................................... 51 
2.3.8 STZ treatment reduced β-cell mass and islet number in CK19-CreERT;Ai9(RCL-tdT) 
mice ....................................................................................................................................... 54 
2.3.9 Glucose tolerance was impaired in STZ-treated CK19-CreERT;Ai9(RCL-tdT) mice ...... 54 
2.3.10 tdTomato labels CK19-expressing cells in the pancreas of CK19-CreERT;Ai9(RCL-tdT) 
mice following tamoxifen administration ............................................................................. 57 
2.3.11 Pancreatic insulin expression diminished following STZ treatment in CK19-
CreERT;Ai9(RCL-tdT) mice ..................................................................................................... 57 
2.3.12 STZ treatment increased the proportion of infiltrating CD45+ cells in the pancreas of 
CK19-CreERT;Ai9(RCL-tdT) mice ........................................................................................... 60 
2.4 Discussion ........................................................................................................................... 62 
3.0 Discussion ................................................................................................................................ 66 
3.1 Summary ............................................................................................................................. 67 
3.2 hMSC CM improved proliferation of murine CK19+ cell in vitro, irrespective of Wnt-
pathway stimulation or inhibition ............................................................................................ 68 
3.3 CK19-CreERT;Ai9(RCL-tdT) mice represent a strong model to characterize CK19+ cell 
contribution to islet regeneration ............................................................................................ 70 
3.4 Leukocyte infiltration plays a role in STZ-mediated pancreatic injury ............................... 72 
3.5 Clinical Implications ............................................................................................................ 74 
3.6 Future Directions ................................................................................................................ 76 
viii 
 
4.0 References .............................................................................................................................. 79 
Curriculum Vitae .......................................................................................................................... 96 
 
 
List of Figures 
Figure 1.1 CHIR99021 and IWR-1 can be used to stimulate or inhibit the canonical Wnt/β -
catenin pathway, respectively. ...................................................................................................... 20 
Figure 1.2. Proposed mechanism for islet cell regeneration in hyperglycemic mice following 
Wnt+ hMSC CM iPan injection. ................................................................................................... 23 
Figure 2.1 Fluorescence-activated cell sorting (FACS) strategy to isolate murine 7-AAD-/DBA 
lectin+ cells. .................................................................................................................................. 31 
Figure 2.2 STZ treatment induced systemic hyperglycemia and increased the proportion of DBA 
lectin+ cells within the pancreas. .................................................................................................. 35 
Figure 2.3 STZ treatment increased the proportion of F4/80+ cells within CD45+ and CK19+ 
cell populations within the pancreas. ............................................................................................ 38 
Figure 2.4 Treatment of hMSC with CHIR99021 increased intracellular β-catenin. ................... 41 
Figure 2.5 Treatment with CHIR99021 did not affect hMSC survival or apoptosis. ................... 42 
Figure 2.6 Treatment of hMSC with IWR-1 did not affect intracellular β-catenin levels. ........... 43 
Figure 2.7 Treatment with IWR-1 did not affect hMSC survival or apoptosis. ........................... 44 
Figure 2.8 Treatment with hMSC CM increased the frequency of proliferating CK19+ cells in 
vitro. .............................................................................................................................................. 47 
Figure 2.9 STZ treatment decreased DBA lectin+ pancreatic cell proliferation in vitro. ............. 49 
Figure 2.10 Epithelial-to-mesenchymal transition and endocrine phenotype acquisition were not 
observed in DBA lectin+ cells exposed to hMSC CM in vitro..................................................... 50 
ix 
 
Figure 2.11 STZ treatment (60 mg/kg/day x 5 days) of CK19-CreERT;Ai9(RCL-tdT) mice 
resulted in elevated glyemia ( ≥15 mmol/l) at Day 14. ................................................................. 52 
Figure 2.12 STZ treatment in CK19-Cre-ERT;Ai9(RCL-tdT) mice decreased β-cell mass and 
islet number. .................................................................................................................................. 55 
Figure 2.13 Glucose tolerance was impaired in STZ-treated CK19-CreERT;Ai9(RCL-tdT) mice.
....................................................................................................................................................... 56 
Figure 2.14 tdTomato labeled CK19-expressing cells in the pancreas following tamoxifen 
treatment in CK19-CreERT;Ai9(RCL-tdT) mice. ........................................................................ 58 
Figure 2.15 STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice decreased the proportion of 
insulin-expressing cells within the pancreas. ................................................................................ 59 
Figure 2.16 STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice increased the proportion of 
CD45+ cells in the pancreas. ........................................................................................................ 61 
Figure 3.1 Proposed experimental strategy for assessing ductal cell contribution to β-cell 
regeneration in CK19-CreERT;Ai9(RCL-tdT) mice. ................................................................... 77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Abbreviations 
7-AAD – 7-Aminoactinomycin D 
ADP – Adenosine diphosphate 
ANOVA – Analysis of variance 
APC – Adenomatous polypsosis coli gene product 
ARX – Aristaless related homeobox 
ATP – Adenosine triphosphate 
AUC – Area under the curve 
AX - Alloxan 
BB - Biobreeding 
BSA – Bovine serum albumin 
CAB – Citric acid buffer 
CD – Cluster of differentiation 
CK1 – Casein kinase 1 
CK19 – Cytokeratin 19 
CM – Conditioned media 
DBA – Dolichos Bifluoros Agglutinin 
DM – Diabetes mellitus 
DMEM/F-12 - Dulbecco-s Modified Eagle Medium/Ham’s F-12 
DMSO – Dimethyl sulfoxide 
DNA-PK – DNA-dependent protein kinase 
EdU – Ethynyldeoxyuridine 
EGF – Epidermal growth factor 
EMT – Epithelial-to-mesenchymal transition 
Ezh2 - enhancer of zeste 2 polycomb repressive complex 2 
FACS – Fluorescence activated cell sorting 
FGF – Fibroblast growth factor 
GIP – Glucose-dependent insulinotropic peptide 
GLP – Glucagon-like peptide 
GLUT – Glucose transporter 
GPCR – G-protein coupled receptor 
xi 
 
GSK3β – Glycogen synthase kinase-3β 
hESC – Human embryonic stem cells 
HFD – High-fat diet 
HGF – Hepatocyte growth factor 
HLA – Human leukocyte antigen 
hMSC – Human multipotent stromal cells 
Hnf1b – Hepatocyte nuclear factor 1 homeobox B 
IDF – International Diabetes Federation 
IFN-γ – Interferon-γ 
IGF-1 – Insulin growth factor 1 
IL-1β – Interleukin 1β 
iPan – Intrapancreatic 
iPSC – Induced pluripotent stem cells 
IRS – Insulin receptor substrate 
ISCT - International Society for Cellular Therapy 
MAF - v-maf musculoaponeurotic fibrosarcoma oncogene homologue 
MFI – Mean fluorescence intensity 
MHC – Major histocompatibility complex 
MSC – Multipotent stromal cells 
NGF – Nerve growth factor 
Ngn3 – Neurogenin 3 
Nkx6.1 – NK6 homeobox 1 
NOD – Non-obese diabetic 
PAX – Paired box 
PBS – Phosphate buffered saline 
PDC – Pancreatic ductal cell 
Pdgfr - platelet-derived growth factor receptor 
PDX-1 – Pancreatic and duodenal homeobox 1 
PERK – Pancreatic endoplasmic reticulum kinase 
Pft1a – Pancreas-specific transcription factor  
Polypeptide – PP 
xii 
 
RNA-seq – Ribonucleic acid sequencing 
ROS – Reactive oxidative species 
SCID – Severe combined immunodeficient 
SD – Standard deviation 
SEM – Standard error of the mean 
STZ - Streptozotocin 
T1D – Type 1 diabetes 
T2D – Type 2 diabetes 
TCF/LEF – DNA-bound T-cell factor/lymphoid enhancer factor 
Th – T helper 
TNF-α – Tumor necrosis factor-α 
VEGF – Vascular endothelial growth factor 
Wnt+ - Wnt-stimulated 
Wnt- - Wnt-inhibited 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.0 Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
1.1 Functions of the Pancreas 
The pancreas, a digestive organ located in the upper left abdominal cavity, is composed of 
exocrine and endocrine tissue. Exocrine cells, including acinar and ductal cells, aid in the digestion 
of food passing from the stomach into the small intestine. Acinar cells synthesize proenzymes, 
which become activated in the duodenum to break down proteins, carbohydrates, and lipids. Ductal 
cells secrete bicarbonate to neutralize acidic chyme from the stomach as it passes into the 
duodenum. Endocrine cells, organized in clusters called islets of Langerhans, synthesize and 
secrete hormones via the portal vein system to regulate glucose homeostasis1. 
 
1.1.1 Human Pancreas Development 
 During human fetal development, the pancreas arises from interactions between the 
endodermal epithelium and surrounding mesenchyme2. Pancreatic organogenesis begins with the 
formation of the pancreatic and duodenal homeobox 1 (Pdx1)- and pancreas-specific transcription 
factor (Ptf1a)-expressing dorsal and ventral buds from the endoderm-derived primitive gut 
epithelium at gestational day 263–5. Subsequently, fusion of these buds forms the definitive 
pancreas with an interconnected ductal network3. As the left ventral bud regresses, later becoming 
the inferior head of the pancreas, the right ventral bud fuses with the dorsal bud during gut rotation 
at 6-7 weeks of gestation, giving rise to the majority of the pancreas4. Between gestational days 45 
and 47, the pancreatic epithelium undergoes active growth, proliferation, and branching 
morphogenesis into the surrounding mesenchyme, controlled by NOTCH, fibroblast growth factor 
(FGF), and epidermal growth factor (EGF) signaling3,4. Compartmentalization of the pancreatic 
tip and trunk occurs at around gestational week 7, with proacinar/tip cells expressing GATA4 and 
bipotent endocrine/ductal progenitor cells expressing Sox9, NK6 homeobox 1 (Nkx6.1), 
hepatocyte nuclear factor 1 homeobox B (Hnf1)b, and Pdx14,6,7. 
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Exocrine tissue, comprised of acinar and ductal cells, makes up >95% of the pancreas8. 
Acinar-specific gene expression of digestive enzyme precursors and other factors mark a distinct 
commitment at around gestational weeks 11-15, including chymotrypsinogen, trypsinogen, 
protease, elastase 1, and subsequently amylase after gestational week 234. Acinar cells are 
connected to ductal tissue through centroacinar cells/terminal duct cells8. Duct cells transport these 
pancreatic zymogens and secrete bicarbonate to neutralize gastric acid into the duodenum8. 
Continued expression of Sox9 and Hnf1b and expression of differentiated ductal cell markers 
including cytokeratin 19 (CK19), carbonic anhydrase 1, mucin 1, and cystic fibrosis membrane 
conductance regulator mark ductal commitment from trunk progenitors at gestational week 114,8. 
However, it remains unclear whether differentiated ductal cells retain the ability to give rise to 
endocrine cells that bipotent trunk precursor cells possess. 
 
The endocrine compartment, which makes up 2-3% of the pancreas, is composed of 
hormone-secreting cells including insulin-secreting β-cells (65-80%), glucagon-secreting α-cells 
(15-20%), somatostatin-secreting δ-cells (3-10%), polypeptide (PP)-secreting PP cells (3-5%), and 
ghrelin-secreting ε-cells (<1%)9–14. Transient expression of the transcription factor Neurogenin 3 
(Ngn3) and paired box (PAX)6 expression mark commitment of bipotent trunk progenitors to an 
endocrine lineage fate3,10,15. As endocrine cells commit to their specific lineages, each cell type 
expresses a unique set of transcription factors. When endocrine cells commit to an α-lineage, they 
express aristaless related homeobox (ARX) and glucagon, but not paired box 4 (PAX4) or PDX115. 
On the other hand, β-cells express PDX1, NKX6.1, v-maf musculoaponeurotic fibrosarcoma 
oncogene homologue (MAF)A, PAX4, and insulin, but not ARX15. It is thought that reciprocal 
inhibition between ARX and PAX4 expression may mark a key checkpoint in specification 
between α- and β-cell identity, respectively16–19. The first endocrine cell type to appear is insulin-
expressing cells at gestational week 7.5, followed by glucagon- and somatostatin-expressing cells4. 
Differentiated endocrine cells migrate away from the ductal epithelium and organize into clusters 
called islets of Langerhans which form during gestational week 10 and obtain a vascular network 
by gestational week 144,8. The majority of α-, β-, and δ-cells within the human pancreas are single 
hormone expressing after birth4. Bi-hormonal expression of insulin and glucagon in approximately 
20-40% of α- and β-cells has been noted between gestational week 9 and 16, which significantly 
declined by gestational week 21 and was predominantly undetectable in the adult pancreas4,15. 
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1.1.2 Glucose Homeostasis and Regulation of Insulin Secretion 
 The human body requires a consistent supply of glucose during all states: well-fed, 
starvation, exercise, rest, or stress20. For example, the human brain requires 6 grams of glucose per 
hour to maintain basic function20. The islets of Langerhans play a crucial role in maintaining 
normoglycemia through secretion of antagonistic hormones, insulin and glucagon, to prevent 
deleterious consequences of hyperglycemia and hypoglycemia. After a meal, absorption of 
carbohydrates causes blood glucose levels to rise. In response to elevated exogenous glucose 
concentrations, circulating blood glucose is taken up from capillaries within and surrounding islets 
by the low affinity facultative glucose transporter (GLUT) 2 (Km=17 mmol/l), located on 
pancreatic β-cells14,21,22. Upon entry into the cell, this glucose enters glycolysis to increase the ratio 
of adenosine triphosphate (ATP) to adenosine diphosphate (ADP)14. An increased ATP/ADP ratio 
leads to closure of ATP-sensitive potassium (K+)-channels and subsequent depolarization of the 
β-cell membrane14. Upon depolarization, voltage-dependent calcium (Ca2+) -channels facilitate the 
influx of Ca2+ ions, which triggers fusion of insulin-containing vesicles with the plasma membrane 
and release of vesicle contents into the blood in a biphasic manner14,23. Circulating insulin is taken 
up primarily by the liver, muscle, and adipose tissue to facilitate insulin-dependent uptake of 
exogenous glucose via GLUT4 from the blood, promoting anabolic processes such as glycogenesis 
and lipogenesis14,24–26. Conversely, when blood glucose levels are low, such as during a fasting 
state, α-cells secrete glucagon which signals hepatocytes to mobilize glucose via glycogenolysis 
to restore normoglycemia. 
 
 Insulin secretion is affected by additional external regulators. Incretin hormones, including 
glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic peptide (GIP) amplify 
insulin secretion27. GLP-1 and GIP are released by enteroendocrine L-cells and K-cells, 
respectively, following nutrient entry into the intestine following oral ingestion28–33. Pancreatic β-
cells can increase the rate of insulin translation in response to the presence of nutrients, regulated 
in part by pancreatic endoplasmic reticulum kinase (PERK) and eukaryotic initiation factor 2a22,34–
36. Conversely, short-chain fatty acids exhibit an inhibitory effect on insulin secretion as a result 
of reduced ATP/ADP ratio following oxidation14,37. The stress hormone norepinephrine also 
inhibits insulin secretion by binding to G-protein coupled receptor (GPCR)-linked α2-adrenergic 
receptors, causing hyperpolarization of β-cells38–40. Proper regulation of insulin secretion and 
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function is critical for energy homeostasis. β-cell dysfunction, a hallmark of diabetes mellitus 
(DM), leads to aberrant glucose homeostasis and long-term complications. 
 
β-cell mass can be dynamic to meet bodily demands and maintain glucose homeostasis 
during pregnancy and weight gain. Studies have shown a linear correlation between β-cell mass 
and body weight and/or body mass index in mice, rats, and humans41–44. β-cell mass is dictated by 
the balance between β-cell production (through replication or neogenesis), β-cell death, and β-cell 
volume changes (hypertrophy or atrophy)44. 
 
1.2 Diabetes Mellitus 
The earliest known report of DM dates back to 1552 BC when Egyptian physician Hesy-
Ra described a disease characterized by frequent urination and rapid weight loss45. Between the 
fifth and sixth centuries, Sushrant recorded an association of these symptoms with sweet-tasting 
urine in Indian literature46. Since then, the emergence of chemical analysis as a diagnostic tool and 
the study of endocrinology have improved our understanding of diabetes pathology46. 
 
Diabetes results from the destruction of insulin-producing β-cells in the pancreas as a 
consequence of autoimmune attack (Type 1) or insulin insensitivity (Type 2), leaving patients 
unable to control blood glucose47. The International Diabetes Federation (IDF) the prevalence of 
diabetes in adults to be 463 million in 2019, which is projected to increase to 700 million by 204548. 
The annual economic burden of diabetes and its cardiovascular co-morbidities has been estimated 
at $825 billion in a systematic review by the Non-communicable Diseases Risk Factor 
Collaboration49. This load is placed on patients and their families, their health infrastructures, and 
national economies49. Thus, there exists an irrefutable need to develop curative therapies for 
diabetes. 
 
1.2.1 Type 1 Diabetes 
Type 1 diabetes (T1D) is an autoimmune disease resulting in the selective destruction of 
pancreatic β-cells by T-lymphocytes22. Typically diagnosed in juvenile patients, T1D is 
characterized by the inability to synthesize and secrete insulin endogenously50. The extent of β-
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cell loss at the presentation of clinical symptoms varies between individuals and is dependent on 
age and cellular pattern of infiltrating cells during insulitis51–54. T1D accounts for <15% of total 
DM cases, with a worldwide prevalence of 1.1 million in children aged 0-19 in 201948,55. The 
worldwide incidence of T1D has been estimated to increase 3% annually, with the greatest increase 
observed in children aged 0-455. 
 
Apoptosis of β-cells in T1D results from immune antibody binding and cellular reactivity 
to endogenous islet antigens. T-cell and macrophage islet infiltration and subsequent release of 
inflammatory cytokines, including interleukin-1β (IL-1β), interferon-γ (IFN-γ), and tumor necrosis 
factor-α (TNF-α), result in T-cell activation and β-cell destruction22,56–61. Following autoantibody 
generation, cluster of differentiation (CD) 4+ naïve T helper (Th) 0 cells polarize towards an 
inflammatory Th1 phenotype. Th1 cells presented with islet self-antigens by antigen presenting 
cells promotes β-cell destruction through release of cytokines and subsequent recruitment of pro-
inflammatory (M1) macrophages and CD8+ cytotoxic T-lympocytes22,62–66. Activated T-
lymphocytes then mediate direct β-cell destruction through the pore-forming perforin-dependent 
pathway or induce apoptosis via Fas/Fas ligand interactions67. Mutations in the human leukocyte 
antigen (HLA) gene, encoding cell surface antigens that facilitate interaction with immune cells, 
correlate to an increased risk in developing T1D68–70. Environmental factors including infant 
nutrition, vitamin D deficiency, gut microbiota, and viral infections may contribute to the 
development of T1D in individuals with genetic predispositions71. Our understanding of the 
underlying causes and progression of T1D is growing with use of advanced technologies including 
artificial intelligence, however, characterization of the disease in humans is complicated by the 
latency between the onset of the autoimmune disease process and presentation of clinical 
symptoms, as well as limited availability of human pancreas tissue for study72–74. 
 
1.2.2 Type 2 Diabetes 
 Glucose homeostasis in the body depends on insulin secretion by pancreatic β-cells and 
normal body cell responses to insulin receptor binding and subsequent glucose uptake75. During 
Type 2 diabetes (T2D) pathogenesis, the response to insulin becomes defective, leading to 
dysregulated glucose balance and metabolism. Of the 463 million people estimated to have 
diabetes by the IDF, individuals aged 20-79 with T2D overwhelmingly dominate this estimation48. 
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Approximately 50% of adults living with diabetes are unaware of their condition because there is 
a long pre-detection period (3-7 years) during which blood glucose levels are elevated but 
symptoms are not clinically diagnosed48,55. Thus, early detection is crucial in improving outcomes 
associated with T2D and associated complications48,55. In developed countries, the annual 
incidence of T2D is estimated at 6.7-7 per 1000 individuals per year55. 
 
 Also termed non-insulin-dependent diabetes, the development and progression of T2D is 
marked by deterioration in the ability to respond to elevated blood glucose levels over several 
years. Progression towards a diabetic state is characterized by a reduction in insulin sensitivity, 
leading to decreased glucose uptake by effector cells76. When the energy balance in the body is 
chronically skewed towards excess calories, fat accumulates in subcutaneous tissue77. When the 
storage capacity of this tissue is exceeded, fatty acids are stored in tissues such as the liver, 
muscles, and in the pancreas77. Fat accumulation in liver and muscle tissue contributes to impaired 
glucose uptake in response to insulin as a result of impaired insulin receptor tyrosine kinase 
activity, while fat in the pancreas contributes to further β-cell dysregulation77–79. Studies suggest 
that this impaired insulin response also stems from dysfunctional glucose storage processes, 
including decreased skeletal muscle glycogenesis and increased gluconeogenesis despite 
hyperinsulinemia76,77,79. Following initial insulin resistance, compensatory mechanisms in 
response to the increased metabolic load, including β-cell mass expansion and increased secretion 
of insulin by β-cells will occur but cannot be sustained over time77,80. Chronic hyperglycemia 
depletes insulin-containing vesicles, reducing the capacity of β-cells to respond to new glucose. 
Glucotoxicity, which is correlated with an increase in reactive oxidative species (ROS), also causes 
stress on β-cells, subsequently leading to β-cell hypertrophy and increased risk of apoptosis81. As 
T2D  progresses, the rate of β-cell apoptosis exceeds the rate of β-cell replication and neogenesis, 
leading to a decline in total β-cell mass80. 
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 Aberrant innate immunity activation also plays a role in the progression of T2D. Increased 
levels of circulating innate immune acute-phase circulating factors, including C-reactive protein, 
serum amyloid A, α-1-acid glycoprotein, sialic acid, and IL-6,  have all been observed in T2D 
patients82. Increased circulating inflammatory cytokines can exacerbate insulin resistance. For 
example, TNF-α activates c-Jun NH2-terminal kinase which inhibits insulin signaling through 
serine phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 and stimulation of 
suppressor of cytokine signaling proteins, which bind and facilitate degradation of IRS-1 and IRS-
283. 
 
 Genetic predispositions also predict susceptibility to T2D. As a polygenic disease, in which 
single mutations can have protective or deleterious effects, scientists have been working to identify 
candidate genes to characterize the genetic components in patients with T2D84. Single nucleotide 
polymorphisms in genes including peroxisome proliferator-activated receptor γ (PPARG), 
potassium inwardly rectifying channel subfamily J member 11 (KCNJ11), Wolfram syndrome 1 
(WFS1) gene, and HNF1b are associated with development of T2D84. In individuals with genetic 
predispositions, environmental factors including high-fat diet, reduced physical activity, age, 
pollutants, and exposure to a diabetic environment in utero contribute to an increased risk of 
T2D85–87. Consequences of chronic hyperglycemia and fat accumulation in organ tissues include 
cardiovascular disease, retinopathy, and neuropathy88. 
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1.2.3 Animal Models to Study Diabetes 
 Animal models of diabetes allow for study of spontaneous or induced pathology that 
resembles one or more aspects of the disease in humans89. Both T1D and T2D are multifactorial 
diseases in which polygenic and environmental components contribute to disease progression. 
 
1.2.3.1 Models for T1D 
 To study autoimmune T1D, the non-obese diabetic (NOD) mouse is commonly used. In 
NOD mice, insulitis starts at approximately 4-5 weeks of age with lymphocytes surrounding islets 
followed by infiltration of an unusually high number of CD4+ and CD8+ T-cells89. Immune cell 
influx ultimately results in destruction of >90% of β-cells and hyperglycemia by weeks 24-30 of 
age89. As in humans, NOD mice develop autoantibodies to insulin, glutamic acid decarboxylase, 
and the tyrosine phosphatase ICA51289. Major histocompatibility complex (MHC) alleles are also 
important factors in disease progression in these mice, similar to humans89. Although clinical 
symptoms typically present in human patients, including hyperglycemia, glycosuria, polydipsia, 
and polyuria, manifest in NOD mice, they have a higher resistance to ketoacidosis and can survive 
up to 2-4 weeks without exogenous insulin89. 
 
 The Diabetes-prone biobreeding (BB) rat has MHC gene susceptibility to autoimmune 
diabetes and develops islet-specific and glutamic acid decarboxylase autoantibodies89,90. Insulitis 
within this rat model is similar to human pathogenesis with Th1-lymphocytes predominating 
infiltration91. At 8-16 weeks of age, rats become hyperglycemic, lack insulin, and exhibit polyuria 
and polydipsia89. Similar to humans, BB rats are prone to ketoacidosis and need exogenous insulin 
treatments to survive91. However, this rat model has depressed levels of CD4+ T-cells and almost 
non-existent CD8+ T-cells91, which compromises its acceptability as a model for human T1D 
diabetes. 
 
 Chemical agents have also been used to model diabetes. Streptozotocin (STZ) and alloxan 
(AX) target pancreatic β-cells via GLUT2 transporter specificity and mediate β-cell death through 
ROS and free radical mechanisms89. STZ, a nitrosourea related antibiotic and antineoplastic agent 
produced by Streptomyces achromogenes, induces DNA alkylation and fragmentation within β-
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cells, leading to β-cell destruction and insulin-dependent diabetes89. Although these chemical 
agents cause hyperglycemia and insulinopenia, they do not recapitulate the autoimmune aspects 
of T1D89,92–94. 
 
1.2.3.2 Models for T2D 
 Spontaneous mouse models of T2D contain genetic mutations that make mice susceptible 
to the development of diabetic-like symptoms. Among these are the ob/ob and db/db mouse strains 
with mutations in the leptin and leptin receptor genes, respectively89. The ob/ob genotype is 
characterized by excessive appetite, low energy expenditure, and obesity starting at approximately 
4 weeks of age89. Following insulin resistance from hyperphagia and obesity, hyperinsulinemia 
ensues89,95. Ob/ob mice derived from the C57BL/6J strain develop mild hyperglycemia, while 
similar mice derived from the C57BL/KS strain develop severe diabetes which may be lethal89,95. 
Db/Db mice also develop hyperphagia, obesity, insulin resistance, and hyperinsulinemia before 
developing hyperglycemia by 8 weeks of age as a result of β-cell failure89,96. 
 
 Non-spontaneous models of T2D include C57BL/6J mice fed a high-fat diet (HFD). HFD 
induces system metabolic alterations consistent with T2D. Disease progression is marked by 
obesity, insulin resistance, subsequent hyperglycemia, and lipid accumulation97. ROS production 
as a result of chronic hyperglycemia causes apoptosis of β-cells and subsequent reduction in β-cell 
mass98,99. Mice fed a HFD also exhibit increased systolic blood pressure compared to those fed a 
low-fat diet100. Similar to human T2D pathogenesis, low level chronic inflammation, including 
within the cardiovascular system, has been identified in HFD mice, which has been attributed to 
immune responses that are more often Th1-mediated99. However, a standardized protocol for this 
model has yet to be established. 
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1.3 Therapeutic Approaches to Treat Diabetes Mellitus 
Scientific and technological advances have played a critical role in developing effective 
treatments for diabetes. Identifying targets and strategies for long term, sustainable treatments has 
been crucial in the advancement of patient care. Treatments for diabetes have primarily focused 
on insulin therapy, gene therapy, cell replacement, and regenerative approaches. Before these 
treatments became available, physicians promoted fasting and calorie-restricted diets for diabetes 
to improve glucosuria and acidosis, and delay negative outcomes in children with diabetes101,102. 
Starting with the discovery of insulin in 1920, finding a curative therapy for diabetes has seemed 
more within reach102. 
 
1.3.1 Drug Treatments 
 Exogenous insulin therapy has become a common treatment for patients with T1D and for 
some with T2D. In 1920, Frederick Banting, an orthopedic surgeon, had the idea to isolate pancreas 
extracts to treat depancreatized dogs that developed diabetes102. Following intravenous injection 
of what Banting and Charles Best termed ‘isletin’, the blood glucose levels of these dogs 
decreased102. After J.B. Collip joined the group in 1921, the team purified isletin for human use, 
and the first injection was given to a 14-year-old boy in 1922102. Improvements in methodology 
for purification over the ensuing years has led to consistent positive clinical outcomes. Subsequent 
development of more potent insulin and short- and long-acting analogs, has led to improved 
physiological control of diabetes symptoms and reduced complications102. Today, insulin therapy 
is given through injections or via an insulin pump and can either be used alone or alongside other 
oral medications to control symptoms. There are many different types of exogenous insulin 
available with differing pharmacokinetic properties, as well as various delivery methods, so 
finding the most suitable therapy for each patient is paramount in maintaining their health. 
However, patients on insulin therapy must continuously monitor their blood glucose and injections 
must be given on a regular basis lifelong. 
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Other pharmacological agents and combination therapies have also been used to control 
blood glucose and other symptoms in patients with diabetes. Metformin is a biguanide that 
increases insulin sensitivity by phosphorylating GLUT-enhancer factors and inhibits hepatic 
gluconeogenesis103,104. Additionally, in combination with an effective treatment plan, metformin 
has been shown to help with weight loss as well as serum triglyceride and low density lipoprotein 
level reduction105. However, it does not affect the activity of β-cells. Sulfonylureas act on the ATP-
sensitive potassium channels of β-cells to trigger insulin secretion106. Efficacy of sulfonylureas 
require the presence of residual β-cell mass and may contribute to exhaustion and death of those 
remaining β-cells103. While there has been tremendous progress in developing pharmacological 
therapies to manage diabetes, they cannot fully recapitulate the refined and complex processes of 
blood glucose homeostasis in healthy persons. Moreover, the cost of medication for patients 
represents a major hurdle for adherence to treatment107. 
 
1.3.2 Gene Therapy 
 Gene therapy refers to the replacement or silencing of dysfunctional genes to treat or 
prevent disease. Gene vectors in the form of lentiviruses, adenoviruses, liposomes, and naked DNA 
have been used for delivery of the insulin gene into various body tissues, including pancreatic, 
liver, fat, and muscle103. One genetic approach to delay the progression of autoimmune diabetes 
and destruction of β-cells targets the immune system itself. Inducing expression of proinsulin 
under control of the MHC class II promoter has been shown to prevent onset of T1D in NOD 
mice108. However, this strategy relies on early detection of immune reactivity to β-cells before 
clinical presentation of symptoms. 
 
 Another gene therapy approach has been the reprogramming of non-β-cells to replace lost 
β-cells through induced expression of β-cell specific transcription factors. For example, 
recombinant-adenovirus-mediated gene transfer of Pdx-1 to hepatocytes of STZ-treated mice 
considerably increased biologically active plasma insulin content and reduced hyperglycemia109. 
Pdx-1 is a crucial regulator in early pancreas morphogenesis and plays an important role in 
controlling glucose-dependent insulin expression in β-cells110. Reprogramming of pancreatic cells 
has also shown some success in recovering β-cell mass. In vivo delivery of adenoviral vectors 
carrying Ngn3, Pdx1, and MafA preferentially reprogrammed pancreatic exocrine cells into β-like 
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cells with indistinguishable morphology and gene expression from endogenous β-cells that could 
ameliorate STZ-induced hyperglycemia111. Pdx1 and MafA-carrying adeno-associated virus 
cassettes administered through the pancreatic duct reprogrammed α-cells into insulin-expressing 
β-cells to restore normoglycemia in in AX-treated or autoimmune NOD mice112. However, long-
term effectiveness of cell reprogramming would have to be combined with treatment strategies to 
combat ongoing autoimmunity or increased metabolic load to improve survival of newly formed 
β-cells. 
 
1.3.3 Cell Replacement Strategies 
 In 2000, James Shapiro and his team published their success in helping seven consecutive 
patients with T1D achieve insulin independence a year after islet transplantation via the Edmonton 
Protocol combined with glucocorticoid-free immunosuppressive therapy to reduce chances of graft 
rejection113. Islets isolated from multiple cadaveric donors matched for blood type and 
lymphocytotoxic antibodies were transplanted to recipients via the hepatic portal vein113. The 
immunosuppressive regimen included long-term sirolimus and tacrolimus use in combination with 
short-term dacluzimab administration113. However, ongoing autoimmunity, graft rejection, and 
adverse responses to immunosuppressive drugs ultimately contributed to rejection of donor 
islets114115. Since then, intensive research has focused on improving outcomes and graft survival 
for patients who have received islet transplants. Data from the Collaborative Islet Transplantation 
Registry indicates a 44% success rate in achieving insulin independence 3 years after surgery116. 
While there have been positive results in the field of allogeneic islet replacement therapy in 
controlling blood glucose and improving glycated hemoglobin levels in diabetic patients via the 
Edmonton Protocol113, shortages of cadaveric donor islets117–119, the necessity for lifelong 
immunosuppressive drugs117–121, and modest success achieving long-term insulin 
independence118,120 have proven to be major barriers to this treatment strategy.  
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 To address the challenge of donor tissue availability, scientists have investigated alternate 
sources of β-cells for transplantation. One attractive source under investigation is pluripotent stem 
cells, including human embryonic stem cells (hESC) or induced pluripotent stem cells (iPSC). 
hESC, first derived from the inner cell mass of blastocysts by James Thompson and his team in 
1998, can give rise to any cell type found in the body when given the appropriate signals116,122. 
iPSC, first described by Shinya Yamanaka in 2006, are reprogrammed adult fibroblast or somatic 
cells that have been reverted to a pluripotent state through introduction of factors including the 
transcription factors Oct3/4, Sox2, c-Myc, and Klf4 in culture116,123. Under stepwise differentiation 
protocols, iPSC can be pushed towards a β-cell lineage that express maturity markers (e.g. insulin, 
MafA, Nkx6.1, Pdx1) through guidance following developmental specification124–128. However, 
of the differentiated endocrine cells generated  in culture, many are polyhormonal and lack 
glucose-dependent insulin secretory ability116. These cultures also contain other pancreatic cell 
types from various developmental stages116. While there has been success in reducing 
hyperglycemia in mice with chemically ablated β-cells, challenges in the application of this 
approach in clinical trials include immune response towards the encapsulation device129,130, 
hypoxia following implantation129–132, and impaired insulin release kinetics132. Ongoing research 
focussed on more efficient generation of insulin-producing β-like cells and encapsulation 
strategies to promote survival have been undertaken by companies such as Semma Therapeutics 
and ViaCyte133. 
 
1.3.4 Endogenous Regeneration of β-cells 
Another strategy under investigation to restore β-cell mass focuses improvement of the 
microenvironment that causes β-cell death. Normally, the adult pancreas exhibits low rates of cell 
turnover and limited response to injury compared to other organs such as the liver or small 
intestine134–136. However, increased β-cell mass in response to pregnancy or obesity suggests that 
the endocrine pancreas may be stimulated to heal under diabetic conditions in the presence of a 
microenvironment that favours regeneration over destruction134,137,138. 
 
One method has targeted regulation of pathways that affect β-cell proliferation. Early in 
life, the primary mechanism of β-cell expansion is through self-replication139,140. However, the 
proliferative capacity of β-cells declines in an age-dependent manner with negligible detectable 
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levels in adults over 30 years old141. One goal within this field is to identify key regulators of β-
cell proliferation that mediate this observed decrease in proliferation over time. An increase in 
expression of p16Ink4a, a cyclin-dependent kinase inhibitor encoded by the Cdkn2a gene, in β-cells 
is strongly correlated with increased age118,142. P16Ink4a expression is inhibited by the epigenetic 
regulator histone-lysine N/methyltransferase enzyme encoded by enhancer of zeste 2 polycomb 
repressive complex 2 (Ezh2), which decreases its expression with age143. Increasing Ezh2 
expression in a transgenic mouse model through direct upregulation or by indirectly targeting 
platelet-derived growth factor receptor (Pdgfr) signaling has shown success in achieving β-cell 
mass expansion through replication143,144. However, translation of findings in regulation of cell 
cycle proteins in humans is difficult, as cell-cycle proteins in rodent islets are different from those 
identified in human islets. High-throughput screens have identified compounds that can stimulate 
β-cell proliferation in human islets such as 5-iodotubercidin, harmine, and WS6145–147. While there 
has been progress in elucidating β-cell regulatory pathways and identifying stimulators of 
proliferation, clinically relevant β-cell mass restoration by β-cell replication alone has proven 
difficult to attain136,148. 
 
Another strategy to stimulate β-cell regeneration focusses on conversion of non-β-cells to 
β-cells in situ. Single-cell ribonucleic acid sequencing (RNA-seq) of human pancreata has revealed 
heterogeneity within cell populations with indication of intermediate stages between lineages, 
which could indicate potential plasticity within the human pancreas149–152. Investigation of this 
potential plasticity has been conducted by the Collombat, Herrera, and Bonner-Weir groups, 
among others18,19,44,153–160. Differentiation studies demonstrated induction of islet-derived 
fibroblast-like cells to hormone-expressing cells in vitro and transition between α- and β-cells 
following induction of lineage specific transcription factors in mouse models, suggesting 
previously unrecognized plasticity between mature endocrine cell types16,18,19,159,161. Expression of 
MafA and Pdx1 in Nng3+/glucagon+ cells resulted in their transition to β-cells in transgenic 
mice159. Following Pax4-mediated α- to β-cell transition, Hnf1β+ duct-lining cells demonstrated 
transient activation of Neurogenin 3, an endocrine progenitor marker, before adopting an α- then 
β-cell phenotype and function19,154,156. Misexpression of Ngn3 in ductal cells stimulated 
reactivation of the endocrine lineage specification pathway, resulting in their transition into 
functional β-like cells in mice154. Supporting the hypothesis that β-cells can be generated from 
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ductal cells in the adult pancreas, 15% of insulin-expressing β-cells, which were not associated 
with other islet cells, have been found in or budding from ductules, paralleling β-cell lineage 
specification processes in the developing pancreas162. These findings have generated interest in 
stimulating islet regeneration during diabetes if we can identify clinically relevant stimuli to 
modulate these regulatory pathways. While Ben-Othman et al. reported that long term gamma-
aminobutyric acid exposure155 and Li et al. reported artemether163 could modestly induce α- to β-
cell transition, subsequent studies have failed to replicate their results164,165. 
 
1.4 Multipotent Stromal Cells 
Stem and progenitor cells from various lineages have been highly studied as a promising 
source of therapeutic properties. Multipotent stromal cells (MSC), also referred to as mesenchymal 
stem cells, have received a high degree of attention in recent years due to their wide range of 
therapeutic actions. The first descriptions of MSC appeared in the 1970s by Friedenstein and his 
team166. Since then, investigation into the therapeutic potential of MSC has been of high interest 
based on their multipotency, secretory, and immunomodulatory functions. Derived from various 
sources within the body, MSC have been considered for therapies for a wide array of diseases 
including myocardial infarction, liver fibrosis, osteoarthritis, and diabetes, among others. 
 
1.4.1 Properties and Characterization 
 The clear definition and criteria of MSC has long been debated. Many investigators have 
reported different methods for isolation, expansion in culture, and criteria for characterizing MSC, 
making comparison and applications of studies in different contexts difficult167. In response, the 
International Society for Cellular Therapy (ISCT) published their minimal criteria for defining 
MSC in 2006167. Their criteria include: plastic adherence; expression of cell surface markers 
CD105, CD73, and CD90 in ≥ 95% of cells in culture, as well as negative expression of CD45, 
CD34, CD14, CD11b, CD19 and HLA isotype DR in ≤ 2% of cells; and the capacity to 
differentiate into bone, fat, and cartilage in vitro167. MSC can be isolated from various human adult 
tissues, including bone marrow168–170, adipose tissue169,171, peripheral blood172,173, lung tissue174,175, 
and muscle tissue176,177. In response to the various tissue sources from which MSC can be derived, 
the ISCT recommended that descriptions of MSC be supplemented by the tissue origin as cells 
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from different tissues exhibit varied phenotype, functions, and secretory profiles178. For example, 
expression of Sox2, a marker associated with the maintenance of multipotency, self-renewal, and 
neurogenesis in early embryonic development, has only been associated with MSC derived from 
bone marrow179. MSC are highly proliferative in vitro, and those isolated from human bone 
marrow have been shown to maintain expression of the stem cell markers Oct-4, Rex-1, and Sox-
2 for at least 10 passages177. However, differences in MSC properties are donor dependent. Among 
different bone marrow donors of varying ages, there are differences in growth kinetics, 
osteogenesis, alkaline phosphatase activity, and secretory profiles180–183. With donor and tissue 
source variability, research geared towards more thorough characterization of MSC, including cell 
subpopulations, is ongoing. 
 
1.4.2 MSC-Mediated Repair 
 MSC have shown great promise as a therapeutic tool for a wide range of diseases and 
disorders. As previously mentioned, one of the criteria for defining MSC is their multipotency. 
When MSC are placed in induction medias supplemented with specific factors, they can be pushed 
down osteogenic, chondrogenic, or adipogenic lineages, which has stimulated interest in tissue 
replacement strategies184–186. While these cells possess the capacity for in vitro multipotency under 
appropriate culture conditions, in vivo engraftment studies have been largely disappointing187–189. 
 
The benefits of MSC cell treatments have predominantly been attributed to indirect or 
paracrine mechanisms. MSC secrete a wide array of factors into the surrounding environment. The 
MSC secretome, which can be concentrated to generate conditioned media (CM), is comprised of 
soluble factors and extracellular vesicles, which together make up a regenerative 
microenvironment containing immunomodulatory, anti-apoptotic, pro-angiogenic, proliferative, 
and growth factors that facilitate tissue repair187,190–192. Important for tissue regeneration, the 
secretome has been shown to include anti-apoptotic growth factors including insulin-like growth 
factor 1 (IGF-1), tissue inhibitor of metalloproteinases 1 and 2, growth hormone, EGF, hepatocyte 
growth factor (HGF), and nerve growth factor (NGF)180. Immunomodulatory functions of MSC 
include promotion of a pro-regenerative macrophage phenotype, mobilization of macrophages to 
the site of injury, limiting degranulation of mast cells, inhibition of lymphocyte proliferation, 
decreasing lymphocyte proinflammatory cytokine synthesis, and increasing lymphocyte anti-
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inflammatory cytokine synthesis180. MSC secrete vascular endothelial growth factor (VEGF) 
which stimulates migration and proliferation of endothelial cells to facilitate the formation of blood 
vessels180,193,194. Treatment using MSC CM has demonstrated regenerative effects in disease 
models including intervertebral disc injury, myocardial infarction, and neuronal damage in a 
preclinical setting, and bone regeneration and alopecia in clinical trials195. Key advantages of this 
approach include: (1) avoidance of immune incompatibility and tumorigenicity associated with 
stem cell administration, (2) MSC CM can be assessed for efficacy, safety, and dosage similarly 
to other pharmaceuticals, and (3) MSC CM can be stored long term without compromising 
effectiveness187. Use of CM also provides the opportunity to engineer production of specific 
factors through modulation of signaling pathways. 
 
1.4.3 MSC as a Therapeutic Option for Diabetes 
 As documented in other tissues, MSC may have the ability to facilitate regeneration of 
pancreatic endorcrine tissue. MSC isolated from human bone marrow have been shown to reduce 
hyperglycemia, increase serum insulin, and stimulate islet regeneration following intravenous 
injection or intracardiac infusion in STZ-treated mice196–200. The immunomodulatory functions of 
MSC have also been shown to delay the onset of hyperglycemia and β-cell loss in mouse models 
of T1D201. Intravenous injection of bone marrow-derived human MSC (hMSC) also improved 
blood glucose levels and ameliorated insulin resistance by increasing GLUT4 expression in a rat 
model of T2D202. However, the mechanisms that mediate these therapeutic actions remain unclear. 
While focusing on the transdifferentiation potential of MSC initially sparked optimism in 
generating insulin-producing cells, low transdifferentation efficiency and engraftment rates have 
limited clinical feasibility exploiting this uncommon property203. Thus, many current studies 
investigating the therapeutic abilities of MSC for treating diabetes focus on paracrine factors. 
Paracrine factors secreted by MSC have been shown to modulate β-cell signalling pathways to 
promote survival and improve glucose-dependent insulin secretion204–206. 
 
 Clinical trials using MSC to treat diabetes have focused primarily on harnessing their 
immunomodulatory properties. Clinically, these cells are an attractive therapeutic option because 
they can be isolated relatively non-invasively from various adult tissues including bone marrow 
and adipose tissue, or from perinatal tissues often discarded, such as the umbilical cord or placenta. 
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Additionally, their rapid expansion in vitro without significant loss in secretory regenerative ability 
add to their clinical applicability203. A number of these studies resulted in reduced insulin 
requirement, increased fasting C-peptide levels, and/or improved HbA1c with few reports of 
adverse events following transplantation into patients203. Some studies have also shown 
improvement of donor islet graft survival when transplanted in combination with MSC203. 
 
 We have previously shown that transplantation of culture-expanded bone marrow-derived 
hMSC also demonstrated the capacity to reduce hyperglycemia and increase β-cell mass by 
stimulating the formation of small ductal-associated islet clusters via paracrine signals in mice 
with STZ-mediated β-cell ablation198–200. The modest short-lived increase in β-cell replication 
could not account for the robust increase in β-cell mass199,200,207. However, regenerative capacity 
was donor-dependent199,200,208,209 and decreased with prolonged expansion199,200. Comparative 
global secretome analyses by mass spectrometry revealed regenerative hMSC (hMSCR) 
exclusively secreted proteins associated with active canonical Wnt/β-catenin signaling, a pathway 
implicated in cell growth, proliferation, and differentiation208. In contrast, non-regenerative 
secretome samples (hMSCNR) contained increased levels of Wnt-pathway inhibitors Dickopf-
1/3208.  
The canonical Wnt/β-catenin signaling pathway has various functions in embryonic 
development and adult homeostasis, including involvement in cell proliferation, polarity, and 
differentiation210. The primary role of this pathway is to regulate nuclear levels of the 
transcriptional co-activator β-catenin. In the absence of signaling ligands, cytoplasmic β-catenin 
is constantly degraded by a destruction complex comprised of Axin, adenomatous polypsosis coli 
gene product (APC), casein kinasae 1 (CK1), and glycogen synthase kinase 3 (GSK3)210. CK1 and 
GSK3 phosphorylate β-catenin for ubiquitination and degradation by proteasomes210. This 
effectively prevents β-catenin from reaching the nucleus and target genes are repressed by the 
DNA-bound T cell factor/lymphoid enhancer factor (TCF/LEF) protein family210. On the other 
hand, activation of this pathway is achieved when a Wnt ligant binds to a Frizzled receptor and 
co-receptor, low-density lipoprotein receptor related protein 6/5210. Subsequent recruitment of 
Dishevelled results in inhibition of the aforementioned destruction complex, preventing 
phosphorylation of β-catenin210. Cytosolic β-catenin accumulates and travels to the nucleus where 
it interacts with TCF/LEF proteins to activate expression of target genes210. Apart from its 
20 
 
 
signalling functions, β-catenin also plays an important role in in cell-cell adhesions211. To assess 
the relevance of the Wnt-pathway to the regenerative capacity of hMSC, Wnt-pathway activation 
was mimicked in hMSCNR cultures using treatment with the glycogen synthase kinase-3β inhibitor 
CHIR99021 for 24 hours in serum-free media before CM collection and concentration207,208. In the 
absence of Wnt ligands, GSK3 marks β-catenin for degradataion212 (Fig. 1.1). Conversely, Wnt-
pathway inhibition was achieved using IWR-1, which stabilizes Axin in the β-catenin inhibition 
complex and ultimately facilitates its degradation213,214.  
 
 
 
 
 
Figure 1.1 CHIR99021 and IWR-1 can be used to stimulate or inhibit the canonical Wnt/β -catenin pathway, respectively. 
Figure 1.1 CHIR99021 and IWR-1 can be used to stimulate or inhibit the canonical Wnt/β-
catenin pathway, respectively. When Wnt ligands bind to their appropriate Frizzled family 
receptor on the plasma membrane, an intracellular signal causes destabilization of the glycogen 
synthase kinase-3β (GSK3)/Axin/Adenomatous Polyposis Coli (APC) inhibition complex, 
preventing the ubiquitination and degradation of cytosolic β-catenin and permitting its 
translocation into the nucleus to affect transcription of genes involved in cell growth, proliferation, 
and differentiation. CHIR99021, a GSK3 inhibitor, activates the Wnt pathway by destabilizing the 
GSK3/Axin/APC inhibition complex, and facilitating nuclear translocation of β-catenin. IWR-1 
stabilizes Axin, and by extension the GSK3/Axin/APC inhibition complex, to promote 
ubiquitination and degradation of cytosolic β-catenin. 
21 
 
 
When co-cultured with human islets for 7 days, Wnt-stimulated (Wnt+) CM enhanced β-
cell survival and proliferation compared to Untreated CM or basal Roswell Park Memorial Institute 
media208. After injection into the pancreas of STZ-treated mice, Wnt+ CM consistently induced 
reversal of hyperglycemia, increased β-cell mass, and improved glucose tolerance compared to 
unconditioned media or Wnt-inhibited (Wnt-) CM injection following intrapancreatic (iPan) 
injection in STZ-treated mice207.  
 
While iPan-injection of Wnt+ hMSC CM reliably rescues hyperglycemia and β-cell mass, 
the identity of ‘signal-receiving cells’ within the pancreas that mediate islet regeneration remains 
unknown. Elucidation of the islet regenerative pathway and identification of the essential effectors 
that stimulate β-cell mass recovery will provide the foundation for a testable cell-free therapy and 
delivery method to reliably induce β-cell regeneration. hMSCR CM contains pro-angionenic 
factors, including FGF7, PDGF, and VEGF-A, which could produce a regenerative 
microenvironment that promotes islet vascularization208. Additionally, hMSCR secrete 
immunomodulatory factors, including TGF-β and stromal cell-derived factor 1 (CXCL12), 
compared to hMSCNR, which secrete elevated levels of pro-inflammatory cytokines, including IL-
1β, IL-6, and IL-8208. Collectively, iPan injection of Wnt+ hMSC CM creates a microenvironment 
that accelerates islet regeneration through its immunomodulatory, anti-apoptotic, pro-angiogenic, 
proliferative, and growth factors that facilitate tissue repair187,190–192. Proteomic analyses and RNA-
sequencing of hMSC CM may prove to be useful tools in elucidating the key factors that 
differentiate regenerative versus non-regenerative samples. Treatment efficacy in strong pre-
clinical models, including NOD mice or db/db mice, will direct future studies in clinical trials. 
 
1.4.4 Elucidating the Islet Regenerative Cascade Induced by hMSC CM 
Analyses of human pancreas donations from healthy and diabetic individuals have revealed 
that insulin-expressing cells budding from pancreatic ducts was more common than observation 
of enlarged islets, indicating more putative regions suggesting neogenesis compared to areas of β-
cell replication or hypertrophy43,44,215. Additionally, expansion of islet-depleted ductal tissue in 
vitro in 3D Matrigel resulted in glucose responsive insulin secreting islet-like clusters budding 
from ductal clusters160,216. Lineage tracing studies have demonstrated transition of duct cells to 
functional β-like cells following transcription factor misexpression, β-cell ablation, or pancreatic 
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injury153,154,156,217,218. This proposed model suggests that ductal cells may act as facultative 
progenitors that contribute to β-cell neogenesis upon experience of stressful conditions. Following 
a dedifferentiation event including epithelial-to-mesenchymal transition (EMT) and transient re-
expression of Ngn3, it is proposed that these cells transition to an α-cell phenotype before 
transitioning to β-like cells153,154,156,217 (Fig. 1.2). Additionally, the Medalist Study, which followed 
411 patients with T1D for ≥ 50 years, showed that 63.4% had C-peptide levels within the minimal 
or sustained range219. Furthermore, during a mixed-meal tolerance test, over half of individuals 
with C-peptide levels ˃0.17 nmol/l responded with a two-fold or greater increase compared to 
fasting levels219. Histological analyses of pancreatic sections from individuals who had passed 
away during the course of the study revealed steady state insulin+ β-cell proliferation219. These 
data support residual β-cell function in patients who have had T1D long-term. Thus, β-cell 
regeneration may be mediated by multiple cell populations, including pre-existing β-cells and 
facultative progenitors within the pancreas. 
 
Following iPan injection, Wnt+ hMSC CM induced a regenerative cascade resulting in the 
emergence of neoislets associated with the ductal epithelium 4 days post-transplantation207. 
Histological analyses revealed detection of glucagon+ cells co-localized with β-cell markers 
insulin, MafA, or Nkx6.1207. Nuclear expression of Nkx6.1 and MafA in newly formed insulin+ 
islets suggested proper β-cell maturation207. Additionally, vimentin+ cell hyperplasia surrounding 
the ductal epithelium was observed following STZ-treatment with or without subsequent hMSC 
CM injection, which is consistent with a model of EMT by the ductal epithelium proposed by other 
groups156,207,220. However, the rate of β-cell proliferation could not account for the robust increase 
in β-cell mass. To address the question of whether these neoislets originate from ductal facultative 
progenitors following Wnt+ CM injection, we proposed to use a lineage tracing mouse model to 
follow the fate of pancreatic CK19-expressing ductal cells. 
 
These lineage tracing mice have a Cre recombinase fused to a murine estrogen receptor 
ligand binding domain inserted upstream of the initiation sequence of the CK19 gene221. 
Expression of CK19, an intermediate filament protein, can ben seen in the adult lung, oral cavity, 
stomach, small intestines, and within the pancreatic, renal, and hepatic ducts221. Following 
administration of tamoxifen, which binds to the fused estrogen receptor, Cre recombinase can 
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access the nuclear compartment of cells to facilitate excision of the loxP-flanked STOP cassette 
flanking the Gt(ROSA)26SOR locus221,222. This permits robust tdTomato fluorescence in cells that 
express CK19, permanently labeling these cells222. This allows for fate-mapping of CK19-
expressing cells through hMSC CM-induced islet regeneration to investigate their contribution to 
the new β-cell population. 
 
 
Figure 1.2. Proposed mechanism for islet cell regeneration in hyperglycemic mice following Wnt+ hMSC CM iPan injection. 
Figure 1.2 Proposed mechanism for islet cell regeneration in hyperglycemic mice following 
Wnt+ hMSC CM iPan injection. We hypothesize iPan injection of Wnt+ hMSC CM will 
stimulate β-cell regeneration from ductal derived facultative precursors following EMT in 
hyperglycemic mice. 
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1.5 Hypothesis and Objectives 
 The overall objective of my thesis was to develop and characterize a model for assessing 
the contribution of CK19-expressing pancreatic duct cells in hMSC Wnt+ CM induced islet 
regeneration.  
 
Based on the recent recognition of islet cell plasticity, we hypothesized Wnt+ hMSC CM 
would stimulate β-cell regeneration from ductal-derived precursor cells after direct injection into 
the pancreas of hyperglycemic mice. 
 
To address this, the following aims were proposed: 
 
(1) To compare the regenerative functions of hMSC CM on isolated CK19-expressing ductal 
cells in vitro. 
 
(2) To characterize a lineage tracing model to assess the contribution of CK19+ ductal cells in 
islet regenerative mechanisms induced by hMSC CM. 
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2.0 Cytokeratin 19-expressing cells as a potential target for islet 
regeneration 
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2.1 Introduction 
 Allogeneic bone marrow transplantation is used to treat hematological cancers, including 
acute myeloid leukemia, to replace unhealthy, cancerous stem cells with healthy ones that 
regenerate the blood system223. The human bone marrow also hMSC, commonly referred to as 
mesenchymal stem/progenitor cells, that serve as long-term precursors for bone, cartilage, fat, and 
muscle cells224. Aside from the support of the self-renewing properties of hematopoietic progenitor 
cells in the bone marrow, MSC also secrete immunomodulatory, anti-apoptotic, pro-angiogenic, 
proliferative, and growth factors187,190–192. The pioneering work by Hess et al.198 has shown that 
transplantation of bone marrow-derived progenitor cells of hematopoietic and mesenchymal 
lineages improved serum insulin levels and reduced hyperglycemia via paracrine mechanisms in 
STZ-treated mice199,200,207,225,226. Follow-up studies have supported the regenerative paracrine 
properties of bone marrow-derived hematopoietic and mesenchymal progenitor cell subtypes that 
stimulate β-cell proliferation or neoislet formation, respectively199,200. Circumventing the 
complications of cellular transplantation, intrapancreatic injection of human bone marrow-derived 
MSC CM has also shown the potential to stimulate islet regeneration and rescue hyperglycemia in 
STZ-treated mice207. 
 
 Diabetes, which is associated with autoimmune β-cell attack (T1D) or insulin resistance 
resulting in β-cell dysfunction (T2D), results in β-cell destruction leaving patients unable to control 
blood glucose levels. With the prevalence of diabetes steadily rising48, and the occurrence of severe 
cardiovascular comorbidities associated with hyperglycemia, investigation into novel curative 
therapies to rescue β-cell mass in patients with T1D and late-stage T2D is highly sought. Currently, 
reduced serum insulin and hyperglycemia are treated with exogenous insulin administration and 
other pharmacological agents to improve glycemic control103. However, these treatments do not 
recapitulate the fine-tuned physiological responses set in motion following nutrient intake and 
patients remain at risk for extreme peaks and troughs in blood glucose levels. Consequently, 
comorbidities are highly prevalent in patients with T2D (>95%), the most common of which are 
severe cardiovascular complications including hypertension, critical limb ischemia, heart attack, 
and stroke227. While islet replacement strategies via the Edmonton Protocol have shown promise 
in helping patients control blood glucose113, shortages of donor tissue117–119, the necessity for 
lifelong immunosuppressive drugs117–121, and compromised long-term success islet survival and 
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sustaining insulin secretion118,120 remain major for islet transplantation. However, β-cell mass 
expansion during pregnancy and obesity suggests β-cells can either proliferate in situ or 
differentiate from progenitor cells upon the generation of a regenerative microenvironment228,229. 
Identification of pathways that regulate β-cell proliferation and/or neogenesis is highly sought in 
regenerating β-cell mass. While β-cell proliferation is the primary driver of neonatal β-cell 
expansion, the proliferative capacity of adult β-cells sharply declines with age141. Although 
targeting pathways that mediate this decline have been of high interest, clinically applicable 
stimulation of β-cell proliferation using biological or pharmacological stimuli has been difficult to 
achieve136,148. Thus, investigation into the regeneration of β-cells from non-β-cell sources remains 
highly relevant. Endocrine cell plasticity has been reported through lineage tracing studies in mice 
whereby non-β-cells, including α-cells or ductal cells, have demonstrated the capacity to transition 
towards the β-cell lineage16,18,19,154,156,157,159,161,230. Because endocrine cells arise from bipotent 
endocrine/ductal trunk cells during embryonic development, it has been hypothesized that 
facultative progenitors reside in the ductal epithelium4,6,7. Thus, a clinically applicable 
stimulator(s) of this dormant β-cell regenerative remains an elusive target in the search for a 
curative therapy for diabetes. 
 
 The regenerative secretome of bone marrow-derived hMSC represent a promising, readily 
available biotherapeutic agent to mediate β-cell mass rescue. hMSC can be rapidly expanded ex 
vivo, and the secretome containing regenerative and immunomodulatory stimuli can be 
concentrated to generate cell-free CM. Although the islet regenerative capacity of hMSC is donor 
dependent after transplantation and diminishes with prolonged culture199,200,207,208, the activity of 
the canonical Wnt/β-catenin signaling pathway has been identified as a key regulator of islet 
regenerative capacity207,208. Small molecule stimulation of the Wnt pathway using the GSK3 
inhibitor CHIR99021 with low-passage hMSC in vitro generated CM that reliably rescued 
glycemia and β-cell mass in hyperglycemic mice. Although increased survival and proliferation of 
human β-cells was observed207,208, neoislets and insulin+ cell clusters were highly localized 
adjacent to ductule regions, and glucagon+ cells within islets co-localized with β-cell markers 
Nkx6.1, MafA, and insulin198–200,207. Thus, harnessing pancreatic plasticity using cell-free hMSC 
CM represents an attractive approach to modulate β-cell mass. While iPan-injection of Wnt+ 
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hMSC CM reliably rescues hyperglycemia and β-cell mass, the identity of ‘signal-receiving cells’ 
within the pancreas that mediate islet regeneration remains unknown. 
 
 To investigate the identity of the ‘signal-receiving’ cell within the pancreas during hMSC 
CM induced islet regeneration, we developed a model to focus on CK19-expressing ductal cells. 
We hypothesized that hMSC CM supplementation in vitro would increase proliferation of murine 
CK19+ pancreas cells and stimulate proliferation. Additionally, we hypothesized that CK19-
CreERT;Ai9(RCL-tdT) mice would reliably label CK19+ cells within the pancreas following 
tamoxifen administration and become hyperglycemic following STZ treatment. CK19-expressing 
cells cultured with hMSC CM exhibited increased proliferation in vitro. However, neither 
epithelial-to-mesenchymal transition nor transition towards an endocrine phenotype were 
observed in vitro following hMSC CM supplementation. Additionally, we characterized a lineage 
tracing mouse model [CK19-CreERT;Ai9(RCL-tdT)] that reliably labelled CK19-expressing cells 
within the pancreas. This model also exhibited hyperglycemia, impaired glucose tolerance, and 
reduced β-cell mass following STZ treatment (60 mg/kg/day x 5 days). These data showcase the 
preparation and optimization of a model that can be confidently used in subsequent experiments 
to assess the contributions of CK19-expressing cells during hMSC CM induced islet regeneration. 
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2.2 Methods 
2.2.1 Assessing pancreatic phenotypic changes in STZ-treated Non-
Obese Diabetic/Severe Combined Immunodeficient (NOD/SCID) mice 
Mice (8-10 weeks old) were administered 35 mg/kg/day STZ by intraperitoneal (i.p.) injection 
for 5 consecutive days. STZ was solubilized in sodium citrate buffer at pH 4.5 and injected into 
mice within 15 min of preparing the mixture. Mice were monitored for non-fasting blood glucose 
and body weight at Days 0, 1, 5, and 10. At each timepoint, pancreata were dissected from 
euthanized mice and digested using collagenase V and trypsin-EDTA. Cells were fixed and 
permeabilized using 10% formalin and 1% Triton X-100. Single cell suspensions were assessed 
for DBA lectin (Vector Laboratories, Burlington, ON) uptake, CK19 (Abcam, Cambridge, UK), 
CD45 (BioLegend, San Diego, CA), and F4/80 (BioLegend) expression by flow cytometry on an 
LSRII flow cytometry machine (BD Biosciences, Mississauga, ON). Flow cytometry data were 
analyzed using FlowJo software (Treestar, Ashland, OR, USA). 
 
2.2.2 Validating the effects of CHIR99021 and IWR-1 on intracellular β-
catenin in hMSC 
Human bone marrow was obtained with informed consent from healthy donors at the London 
Health Sciences Centre (London, ON, Canada). hMSC were purified using density gradient 
centrifugation and cultured in supplemented AmniomaxTM media (Invitrogen, Carlsbad, CA) for 
expansion199,200. Low passage (P3-P4), 80% confluent hMSC cultures were washed with 
phosphate-buffered saline (PBS) to remove serum and growth factors, then cultured in serum-free 
basal AmniomaxTM media supplemented with increasing concentrations of CHIR99021 (0 µM, 5 
µM, 10 µM, 15 µM, 20 µM; AbMole Bioscience, Houston, TX) or IWR-1 (0 µM, 10 µM, 20 µM, 
30 µM, 50 µM, Sigma-Aldrich, St. Louis, MO). In cell cultures without CHIR99021 or IWR-1, 
dimethyl sulfoxide (DMSO) was added as a vehicle control. Cells were fixed in 10% formalin and 
permeabilized using 1% Triton X-100. hMSC were assessed for survival [(7-Aminoactinomycin 
D, 7-AAD (BioLegend)], apoptosis [(Annexin V (BD Biosciences)], and β-catenin (Invitrogen) 
expression by flow cytometry at the London Regional Flow Cytometry Facility and analyses were 
performed using Flowjo software. 
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2.2.3 Generating hMSC CM 
Low passage (P4), 80% confluent hMSC were washed with PBS to remove serum and growth 
factors and cultured in serum-free basal AmniomaxTM media supplemented with either DMSO 
(vehicle control), 10 µM CHIR99021, or 20 µM IWR-1 for 24h to generate Untreated, Wnt+, and 
Wnt- CM, respectively. CM was collected and concentrated ( 40-fold) by centrifugation at 4,100 
g for 75 minutes using 3 kDa filter spin columns. Secreted contents ˃3 kDa separated by the filter 
were collected and the CM protein concentration was quantified using a NanoDrop analyzer. 
 
2.2.4 Murine ductal cell culture and hMSC CM supplementation 
Pancreata from healthy or STZ-treated adult mice (8-10 weeks old) were purified using 
fluorescence activated cell sorting (FACS) at the London Regional Flow Cytometry Facility 
(London, ON) to obtain 7AAD-/Dolichos Bifluorus Agglutinin (DBA) lectin+ cells following 
collagenase V and trypsin EDTA-mediated tissue digestion according to the protocol previously 
outlined by Reichart et al231 (Fig. 2.1). 7-AAD marks dead cells with compromised membrane 
integrity by intercalating double-stranded DNA232. DBA lectin has carbohydrate specificity toward 
α-linked N-acetylgalactosamine common on ductal epithelial cells233. DBA lectin+ cell cultures 
were first established in complete pancreatic ductal cell (PDC) media [Dulbecco-s Modified Eagle 
Medium/Ham’s F-12 (DMEM/F-12) + 5% Nu Serum, 25 μg/ml bovine pituitary extract, 0.5% 
ITS+ (insulin, human transferrin, selenous acid) Premix, 20 ng/ml epidermal growth factor, 1μM 
dexamethasone, 5 mg/ml glucose, 1.22 mg/ml nicotinamide] for 24 hours before replacing media 
with either complete PDC media, basal DMEM/F-12, or DMEM/F-12 supplemented with 
Untreated, Wnt+, or Wnt- hMSC CM (protein dose of 8µg/ well for approximately 8,000 cells) for 
2 or 5 days at 37℃ + 5% CO2. Cell cultures were assessed for proliferative response using 
ethynyldeoxyuridine (EdU) incorporation following 24h pulse label at 50 μM, and phenotype 
transition (vimentin, insulin, glucagon expression) was assessed by immunofluorescence. Ductal 
cell phenotype was verified using CK19 labeling. 
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Figure 3Figure 2.1 Fluorescence-activated cell sorting (FACS) strategy to isolate murine 7-AAD-/DBA lectin+ cells. 
Figure 2.1 Fluorescence-activated cell sorting (FACS) strategy to isolate murine 7-AAD-
/DBA lectin+ cells. (A) Representative photomicrograph of a mouse pancreas section for DBA 
lectin showed cellular co-localization with CK19. Pancreata from mice (8-10 weeks old) were 
digested and single cell suspension was purified by FACS with a strategy for (B) live (7-AAD-) 
cells, (C) setting a gate for DBA lectin using unstained samples, and (D) sorting for DBA lectin+ 
cells. 
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2.2.5 Optimization of STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice 
CK19-CreERT;Ai9(RCL-tdT) mice (8-12 weeks old) [breeding CK19-CreERT mice (Jackson 
Labs, Bar Harbor, Maine, USA) with Ai9(RCL-tdT) mice (Jackson Labs, Bar Harbor, Maine, 
USA)] were treated with increasing concentrations of STZ (40 mg/kg/day, 50 mg/kg/day, 60 
mg/kg/day, or 65 mg/kg/day) dissolved in citric acid buffer (CAB) for 5 consecutive days by i.p. 
injection and assessed for non-fasting blood glucose and body weight at Days 0, 7, 10, and 14.  
 
2.2.6 Islet size, number, and β-cell mass quantification 
Pancreata from STZ-treated CK19-CreERT;Ai9(RCL-tdT) mice sacrificed at Day 14 were frozen 
in optimal cutting temperature media and sectioned (12 μm) so each of the 3 sections per slide 
were >150 μm apart. Sections were fixed in formalin, blocked with peroxidase block and horse 
serum, and stained for insulin using a mouse insulin primary antibody (Sigma) and detected using 
a peroxidase anti-mouse secondary antibody (Vector Laboratories).  ImmPACT™ DAB (Vector 
Laboratories) staining was performed to detect antibody binding, followed by hematoxylin 
counterstain and mounting in Vectamount (Vector Laboratories). A minimum of 10 clustered 
insulin+ cells was required to be classified as an islet. Islet number and size were quantified using 
light microscopy and ImageScope x64 software, counting all islets within 3 sections per mouse. 
β-cell mass was calculated by: 
 
β cell mass =
𝛽 𝑐𝑒𝑙𝑙 𝑎𝑟𝑒𝑎
𝑇𝑜𝑡𝑎𝑙 𝑝𝑎𝑛𝑐𝑟𝑒𝑎𝑠 𝑠𝑒𝑐𝑡𝑖𝑜𝑛 𝑎𝑟𝑒𝑎
𝑥 𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 
 
2.2.7 Glucose tolerance test 
CK19-CreERT;Ai9(RCL-tdT) mice treated with 60 mg/kg/day of STZ (Days 1-5) and CAB 
control mice were fasted for 3 hours on Day 14 before receiving bolus glucose (2 mg/kg) by i.p. 
injection. Blood glucose was assessed at 0, 5, 10, 15, 30, 45, 60, 90, and 120 minutes. 
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2.2.8 Assessing pancreatic phenotypic changes in STZ-treated CK19-
CreERT;Ai9(RCL-tdT) mice 
Mice (8-10 weeks old) were administered 6 mg tamoxifen dissolved in corn oil by oral gavage. 
After 7 days of rest, mice were treated with 60 mg/kg/day STZ by i.p. injection for 5 consecutive 
days. Mice were monitored for non-fasting blood glucose and body weight at Days 0, 1, 7, and 
14. At each timepoint, pancreata were dissected and digested using collagenase V and TrypLE 
(Thermo Fisher). Cells were fixed and permeabilized using 10% formalin and 1% Triton X-100. 
Single cell suspensions were assessed for tdTomato, CK19 (Abcam), insulin (BD Biosciences), 
and CD45 (BioLegend) expression by flow cytometry. Data were analyzed using FlowJo 
software. 
 
2.2.8 Statistical Analysis 
All data was expressed as mean ± standard deviation (SD) unless otherwise stated. Analysis was 
performed by a two-way analysis of variance (ANOVA) for blood glucose curves, and by one-
way ANOVA followed by Tukey’s multiple comparison test for all other analyses, unless 
otherwise stated. 
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2.3 Results 
2.3.1 STZ treatment induced systemic hyperglycemia and increased the 
frequency of DBA lectin+ cells within the pancreas 
To investigate the effects of STZ on mouse CK19, CD45 (pan-leukocyte marker), DBA lectin 
(binds to the α-linked N-acetylgalactosamine carbohydrate moiety), and F4/80 (mouse 
macrophage marker) expression, NOD/SCID mice were injected with 35 mg/kg/day of STZ for 5 
consecutive days and mouse pancreata were harvested and assessed for the frequency of CD45+, 
CK19+, and DBA lectin+ expression at Days 0, 1, 5, and 10 (Figure 2.2D-I). Mice demonstrated 
increased non-fasting blood glucose levels at Day 10 compared to Days 0, 1, and 5 (Figure 2.2A). 
Additionally, the proportion of insulin+ cells was significantly decreased at Days 1 and 10, while 
the proportion of glucagon+ cells did not change across time (Figure 2B,C). While the proportion 
of CD45+ and CK19+ within the pancreas did not change over time, the proportion of DBA lectin+ 
cells was significantly increased at Day 10 compared to Day 0 (Figure 2.2J and K). While CK19 
expression is commonly used as a pancreatic ductal marker, it requires cell fixation and 
permeabilization for detection234. However, to purify viable ductal cells for subsequent culture, 
identification of a live cell marker was required. Various studies have cited DBA lectin as a ductal 
epithelial marker within the pancreas231,233,235–240. However, DBA lectin can also bind non-
specifically to some hematopoietic cells including macrophages241–244. Within the DBA lectin+ 
cell population, the proportion of CK19+ cells was enriched two-fold compared to ungated cells 
(≈ 40% vs. ≈ 20%, respectively)(Figure 2.2 H). In contrast, the proportion of CD45+ cells within 
DBA lectin+ cells did not change compared to ungated cells. Although the DBA lectin+ cell 
population was comprised of 20% hematopoietic cells, isolation of live DBA lectin+ cells by 
FACS followed by 24-hour culture in complete PDC media resulted in 83% CK19+ cell purity 
(CK19+/DAPI+ cells). Therefore, isolation of pancreatic DBA lectin+ cells followed by culture in 
complete PDC media represents a purification strategy for murine CK19+ ductal epithelial cells. 
 
 
 
 
 
35 
 
 
 
 
 
Figure 4 Figure 2.2 STZ treatment induced systemic hyperglycemia and increased the proportion of DBA lectin+ cells within the 
pancreas. 
Figure 2.2. STZ Treatment induced systemic hyperglycemia and increased the proportion of DBA lectin+ cells within the  
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Figure 2.2 STZ treatment induced systemic hyperglycemia and increased the proportion of 
DBA lectin+ cells within the pancreas. NOD/SCID mice (8-10 weeks old) were treated with 35 
mg/kg/day STZ for 5 days (Days 1-5). At Day 0 (n=3-4), Day 1 (n=4), Day 5 (n=4), and Day 10 
(n=7) mouse pancreata were assessed for insulin+, glucagon+, DBA lectin+, CK19+, and CD45+ 
cell frequencies by flow cytometry. (A) At Day 10 mice demonstrated significantly increased non-
fasting blood glucose levels compared to all other timepoints. (B) The proportion of insulin+ β-
cells was significantly decreased at Days 1 and 10 compared to Day 0. (C) The proportion of 
glucagon+ α-cells did not change across time. Representative plots for DBA lectin+, CK19+, and 
CD45+ cells are shown at (D-F) Day 0 and (G-I) Day 10. (J) The proportion of DBA lectin+ cells 
was significantly increased at Day 10 compared to Day 0 (*p<0.05). The proportions of CK19+ 
and CD45+ cells showed no change with time. (I) Within the DBA lectin+ cell population, the 
proportion of CK19+ cells was enriched two-fold compared to ungated cells. In contrast, the 
proportion of CD45+ cells within DBA lectin+ cells did not change compared to ungated cells. 
Data represent mean ± SD compared using a one-way ANOVA followed by Tukey’s multiple 
comparison test. (**p<0.01, ***p<0.001) 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
 
2.3.2 STZ treatment increased the proportion of F4/80+ cells within 
CD45+ and CK19+ cells within the pancreas 
To assess potential  macrophage infiltration in response to STZ treatment, mouse pancreata were 
assessed for F4/80+ expression, a widely used mouse macrophage marker245–247 (Figure 2.3 A-D). 
At Day 10, increased hematopoietic macrophage infiltration was observed, as there was an increase 
in the proportion of F4/80+ cells within the pancreas and within the CD45+ cell compartment 
compared to Day 0 (Figure 2.3E,F). Within the CK19+ cell population, the proportion of F4/80+ 
cells was increased at Day 5 compared to Day 1 (Figure 2.3G). Within DBA lectin+ cells, the 
proportion of F4/80+ cells remained unchanged with time (Figure 2.3H). Collectively, these data 
suggest that macrophage infiltration was observed following STZ treatment, which may play a 
role in islet destruction. 
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Figure 5Figure 2.3 STZ treatment increased the proportion of F4/80+ cells within CD45+ and CK19+ cell populations within the 
pancreas. 2.3. STZ treatment increased the proportion of F4/80+ cells within CD45+ and CK19+ cell populations within the  
39 
 
 
Figure 2.3 STZ treatment increased the proportion of F4/80+ macrophages within CD45+ 
and CK19+ cell populations within the pancreas. NOD/SCID mice (8-10 weeks old) were 
treated with 35 mg/kg/day STZ for 5 days (Days 1-5). At Day 0 (n=3-4), Day 1 (n=4), Day 5 (n=4), 
and Day 10 (n=7), mouse pancreata were assessed for DBA lectin+, CK19+, CD45+, and F4/80+ 
cell frequencies by flow cytometry. (A) Representative dot plots showing the overall proportion 
of F4/80+ macrophages in the pancreas at each timepoint are shown. (B) Representative dot plots 
showing the proportion of F4/80+ cells within CD45+ leukocytes at each timepoint are shown. (C) 
Representative dot plots showing the proportion of F4/80+ macrophages within CK19+ ductal 
cells at each timepoint. (D) Representative dot plots showing the proportion of F4/80+ cells within 
DBA lectin+ cells at each timepoint. (E) The proportion of F4/80+ macrophages in the pancreas 
was significantly increased at Day 10 compared to Day 0. (F) The proportion of F4/80+ 
macrophages within CD45+ leukocytes was significantly increased at Day 10 compared to Day 0. 
(G) The proportion of F4/80+ macrophages within the CK19+ ductal cell population was 
significantly increased at Day 5 compared to Day 1. (H) The proportion of F4/80+ macrophages 
remained unchanged within the DBA lectin+ cell population over the 10-day time course. Data 
represent mean ± SD compared using a one-way ANOVA followed by Tukey’s multiple 
comparison test (*p<0.05). 
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2.3.3 Treatment of hMSC with CHIR99021 increased intracellular β-
catenin and did not affect cell survival 
As the GSK3 inhibitor CHIR99021 promotes destabilization of the β-catenin destruction complex, 
increasing intracellular stores of β-catenin which affects transcription of factors implicated in cell 
growth, proliferation, and differentiation208. Therefore, we sought to titrate CHIR99021 treatment 
concentration to optimally stimulate the Wnt pathway in cultured hMSC, measured by intracellular 
β-catenin levels208,248,249. Following 24-hour treatment, hMSC treated with 10 μM, 15 μM, or 20 
μM CHIR99021 in serum-free basal AmniomaxTM media showed significantly increased mean 
fluorescence intensity (M.F.I.) of intracellular β-catenin by flow cytometry compared to the 
DMSO control (0 μM) and 5 μM treatment (***p<0.001)(Figure 2.4). Treatment with 5 μM 
showed no difference in β-catenin M.F.I. compared to the DMSO control. There were no 
significant differences in the frequency of dead cells (7AAD+/Annexin V+) or apoptotic cells 
(7AAD-/Annexin V+) between any of the treatment conditions (Figure 2.5). Thus, 10 μM 
CHIR99021 was chosen to optimally stimulate the canonical Wnt/β-catenin pathway in hMSC. 
 
2.3.4 Treatment of hMSC with IWR-1 did not affect intracellular β-
catenin or cell survival 
In contrast, IWR-1 stabilizes Axin, and by extension promotes the intracellular destruction of β-
catenin resulting in the blockade of canonical Wnt/β-catenin signaling. Next, we sought to titrate 
the optimal IWR-1 treatment concentration to inhibit the Wnt-pathway in cultured hMSC, as 
measured by intracellular β-catenin levels208,214,249. Following 24-hour treatment, hMSC treated 
with 10 μM, 20 μM, 30 μM, or 50 μM IWR-1 in basal AmniomaxTM media surprisingly showed 
no significant difference in intracellular β-catenin M.F.I. by flow cytometry compared to the 
DMSO control (0 μM) (Figure 2.6). In addition, here were also no significant differences in the 
frequency of dead cells (7AAD+/Annexin V+) or apoptotic cells (7AAD-/Annexin V+) between 
the treatment conditions (Figure 2.7). These results contradict previous findings which identified 
20 μM IWR-1 treatment to optimally inhibit the Wnt/β-catenin pathway207,208. 
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Figure 6 2.4 Treatment of hMSC with CHIR99021 increased intracellular β-catenin. 
Figure 2.4 Treatment of hMSC with CHIR99021 increased intracellular β-catenin. Low 
passage (P3-P4), 80% confluent hMSC (N=5) were treated with 5 μM, 10 μM, 15 μM, or 20 μM 
of CHIR99021 or DMSO (0 μM) for 24 hours in basal Amniomax™ media and assessed for 
intracellular β-catenin M.F.I. by flow cytometry. (A-E) Representative β-catenin vs. SSC-A dot 
plots for 0 μM, 5 μM, 10 μM, 15 μM, and 20 μM treatments with CHIR99021 are shown. (F) 
Treatment with 10 μM, 15 μM, and 20 μM of CHIR90021 significantly increased β-catenin M.F.I. 
compared to the DMSO control (***p<0.001). Data represent mean fold change ± SD compared 
using a one-way ANOVA followed by Tukey’s multiple comparison test. Means with different 
letters represent significantly different values. 
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Figure 72.5 Treatment with CHIR99021 did not affect hMSC survival or apoptosis. 
Figure 2.5 Treatment with CHIR99021 did not affect hMSC survival or apoptosis. Low 
passage (P3-P4), 80% confluent hMSC (N=5) were treated with 5 μM, 10 μM, 15 μM, or 20 μM 
of CHIR99021 or DMSO (0 μM) for 24 hours in basal Amniomax™ media and assessed for cell 
death (7-AAD+) and apoptosis (Annexin V+) by flow cytometry. (A-E) Representative dot plots 
for 7-AAD and Annexin V for 0 μM, 5 μM, 10 μM, 15 μM, and 20 μM treatment with CHIR99021 
are shown. Treatment with CHIR99021 did not alter (F) cell death (proportion of 7-
AAD+/Annexin V+ cells) or (G) apoptosis (7-AAD-/Annexin V+ cells). Data represents mean ± 
SD compared using a one-way ANOVA. 
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Figure 82.6 Treatment of hMSC with IWR-1 did not affect intracellular β-catenin levels. 
Figure 2.6 Treatment of hMSC with IWR-1 did not affect intracellular β-catenin levels. 
Low passage (P3-P4), 80% confluent hMSC (N=4) were treated with 10 μM, 20 μM, 30 μM, or 
50 μM of IWR-1 or DMSO (0 μM) for 24 hours in basal Amniomax™ media and assessed for 
intracellar β-catenin M.F.I. by flow cytometry. (A-E) Representative β-catenin vs. SSC-A dot 
plots for 0 μM, 10 μM, 20 μM, 30 μM, and 50 μM IWR-1 are shown. (F) Treatment with IWR-1 
did not alter β-catenin M.F.I. compared to DMSO (0 μM) control. Data represent mean fold 
change ± SD compared using a one-way ANOVA. 
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Figure 92.7 Treatment with IWR-1 did not affect hMSC survival or apoptosis. 
Figure 2.7 Treatment with IWR-1 did not affect hMSC survival or apoptosis. Low passage 
(P3-P4), 80% confluent hMSC (N=3) were treated with 10 μM, 20 μM, 30 μM, or 50 μM of IWR-
1 or DMSO for 24 hours in basal Amniomax™ media and assessed for cell death (7-AAD+) and 
apoptosis (Annexin V+) by flow cytometry. (A-E) Representative dot plots for 7-AAD and 
Annexin V are shown for 0 μM, 10 μM, 20 μM, 30 μM, and 50 μM IWR-1. Treatment with IWR-
1 did not alter the proportion of (F) dead cells (7-AAD+/Annexin V+) or (G) apoptotic cells (7-
AAD-/Annexin V+) compared to DMSO (0 μM). Data represents mean ± SD compared using a 
one-way ANOVA. 
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2.3.5 hMSC CM stimulated proliferation of CK19+ cells in vitro 
To investigate the effects of hMSC CM supplementation on cultured CK19-expressing cells, 
FACS isolated 7-AAD-/DBA lectin+ cells from healthy or STZ-treated (35 mg/kg/day) 
NOD/SCID mice (8-10 weeks old) were cultured in complete PDC media for 24 hours to facilitate 
cell adhesion. Cell media was then replaced either with complete PDC media, basal DMEM/F-12, 
or DMEM/F-12 supplemented with Untreated, Wnt+, or Wnt- hMSC CM. After 2 or 5 days, 
CK19+ cells were assessed for proliferation (24-hour EdU pulse label). After 2 days in culture, 
DBA lectin+ cells isolated from healthy mice supplemented with Untreated, Wnt+, or Wnt- CM 
showed significantly increased frequencies of proliferating CK19+ cells compared to basal 
DMEM/F-12 (Figure 2.8F). Ductal cell cultures with bovine serum albumin (BSA) showed no 
significant change in proliferation frequency, indicating that hMSC CM benefits were not a result 
of generic protein supplementation in culture. After 5 days culture, there was no significant 
difference in the frequencies of proliferating CK19+ cells between hMSC CM supplemented and 
basal DMEM/F-12 conditions. DBA lectin+ cells isolated from STZ-treated mice showed no 
difference in the frequency of proliferating CK19+ cells after 2 or 5 days in culture (Figure 2.8G). 
Additionally, DBA lectin+ cells purified from STZ-treated mice exhibited decreased frequencies 
of EdU+/CK19+ cells compared to cells isolated from healthy mice after 2 days culture (Figure 
2.9). 
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2.3.6 Epithelial-to-mesenchymal transition and endocrine phenotype 
acquisition were not observed in DBA lectin+ cells exposed to hMSC CM 
in vitro 
While hMSC CM supplementation increased CK19-expressing cell proliferation in vitro, the next 
point of interest was whether hMSC CM affected cell phenotype and differentiation. FACS 
purified 7AAD-/DBA lectin+ cells from healthy or STZ-treated mice cultured in complete PDC 
media, basal DMEM/F-12, or DMEM/F-12 supplemented with Untreated, Wnt+, or Wnt- hMSC 
CM for 2, 4, or 7 days did not show colocalization of vimentin and CK19, suggesting no EMT was 
observed in vitro. Similarly, endocrine phenotype transition was not observed, as colocalization of 
glucagon or insulin with CK19 was not identified at each of these timepoints (Figure 2.10). Thus, 
mesenchymal or endocrine phenotype transition were not observed under these culture conditions, 
future studies can look at earlier markers of mesenchymal or endocrine phenotype, including 
mRNA or transcription factor changes. 
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Figure 102.8 Treatment with hMSC CM increased the frequency of proliferating CK19+ cells in vitro. 
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Figure 2.8 Treatment with hMSC CM increased the frequency of proliferating CK19+ cells 
in vitro. FACS isolated 7-AAD-/DBA lectin + cells from healthy or STZ-treated 8-10 week-old 
mice were cultured in (A) complete PDC media, (B) basal DMEM/F-12, or DMEM/F-12 
supplemented with (C) Untreated, (D) Wnt+, or (E) Wnt- hMSC CM (N=4). After 2 or 5 days, 
CK19+ cells were assessed for proliferation [EdU incorporation following 24h pulse label (50 
μM)]. Arrows indicate DAPI+/CK19+/EdU+ cells. (F) DBA lectin+ cells from healthy mice 
cultured in DMEM/F-12 supplemented with Untreated, Wnt+, or Wnt- hMSC CM showed 
significantly increased frequencies of EdU+/CK19+ cells after 2 days of culture compared to DBA 
lectin+ cells cultured in basal DMEM/F-12. After 5 days culture, there was no significant 
difference in the frequency of EdU+/CK19+ cells between CM supplemented cultures and culture 
in basal DMEM/F-12. (G) DBA lectin+ cells isolated from STZ-treated mice showed no 
significant difference in the frequency of proliferating CK19+ cells after 2 or 5 days in culture. 
Data represent mean ± SD compared using a one-way ANOVA followed by Tukey’s multiple 
comparison test comparing back to DMEM/F-12 for each timepoint (*p<0.05, **p<0.01). 
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Figure 112.9 STZ treatment decreased DBA lectin+ pancreatic cell proliferation in vitro. 
Figure 2.9 STZ treatment decreased DBA lectin+ pancreatic cell proliferation in vitro. FACS 
purified 7-AAD-/DBA lectin+ pancreatic cells from 8-10 week-old healthy or STZ-treated mice 
were cultured in complete PDC media, basal DMEM/F-12 media , or DMEM/F-12 supplemented 
with Untreated, Wnt+, or Wnt- hMSC CM for 2 or 5 days. DBA lectin+ cells purified from STZ-
treated mice exhibited decreased frequencies of EdU+/CK19+ cells compared to cells isolated 
from healthy mice at (A) 2 days or (B) 5 days of culture (N=2-4). Data represent mean ± SD 
compared using a two-way ANOVA followed by Tukey’s multiple comparison test (**p<0.01, 
***p<0.001). 
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Figure 122.10 Epithelial-to-mesenchymal transition and endocrine phenotype acquisition were not observed in DBA lectin+ cells 
exposed to hMSC CM in vitro. 
Figure 2.10 Epithelial-to-mesenchymal transition and endocrine phenotype acquisition were 
not observed in DBA lectin+ cells exposed to hMSC CM in vitro. FACS purified 7-AAD-/DBA 
lectin+ cells from healthy or STZ-treated mice were cultured in complete PDC media, basal 
DMEM/F-12 media, or DMEM/F-12 supplemented with Untreated, Wnt+, or Wnt- hMSC CM in 
DMEM/F-12 for 2, 4, or 7 days. Representative photomicrographs of (A) mouse islets and (B) 
DBA lectin+ cells (cultured in DMEM/F-12 supplemented with Wnt+ CM) stained for vimentin 
and CK19. No co-localization of vimentin and CK19 was observed. Representative 
photomicrographs of (C) a mouse pancreas section and (D) DBA lectin+ cells (cultured in 
DMEM/F-12 supplemented with Wnt+ hMSC CM) showed no co-localization of glucagon or 
insulin (not shown) with CK19. 
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2.3.7 STZ Treatment (60 mg/kg/day x 5 days) induced hyperglycemia in 
CK19-CreERT;Ai9(RCL-tdT) mice 
To assess the optimal STZ dose to induce hyperglycemia and reduce β-cell mass, CK19-
CreERT;Ai9(RCL-tdT) mice (8-12 weeks old) were treated with 40, 50, 60, or 65 mg/kg/day STZ 
for 5 consecutive days (Days 1-5). On Days 0, 7, 10 and 14, mice were assessed for non-fasting 
blood glucose and body weight. Treatment with 60 mg/kg/day of STZ resulted in significantly 
increased non-fasting blood glucose levels at Day 14 compared to Day 0 and Day 7 (Figure 2.11A). 
Treatment with 40, 50, or 65 mg/kg/day showed no differences in non-fasting blood glucoses over 
time. There were no significant differences in the area under the curve (A.U.C.) for blood glucose 
between Days 0 and 14 for STZ-treated mice compared to CAB control mice (Figure 2.11B). 
Assessing differences between the effects of STZ administration in males vs. females on blood 
glucose, male mice administered 60 mg/kg/day exhibited significantly increased non-fasting blood 
glucose levels at Day 14 compared to Day 7 (Figure 2.11C). No differences over time were 
observed in other male/female groups administered STZ. There were no significant differences in 
A.U.C. for blood glucose between males/females administered STZ compared to CAB control 
mice (Figure 2.11D). Mice treated with 50, 60, or 65 mg/kg/day of STZ demonstrated weight loss 
(D14/D0) compared to CAB control mice, which should be monitored upon further 
experimentation and extension of the model (Figure 2.11E). Among STZ-treated mice, those 
administered 60 mg/kg/day produced the highest proportion (30%) of mice with non-fasting blood 
glucose levels ≥15 mmol/l at Day 14 (Figure 2.11F). Mice deemed hyperglycemic and suitable for 
hMSC CM transplantation should have non-fasting blood glucose between 15 and 25 
mmol/l199,200,207,225,226. 
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Figure 132.11 STZ treatment (60 mg/kg/day x 5 days) of CK19-CreERT;Ai9(RCL-tdT) mice resulted in elevated glyemia (>15 mmol/l) 
at Day 14. 
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Figure 2.11 STZ treatment (60 mg/kg/day x 5 days) of CK19-CreERT;Ai9(RCL-tdT) mice 
resulted in elevated glycemia ( ≥ 15 mmol/l) at Day 14. CK19-CreERT;Ai9(RCL-tdT) mice 
(8-12 weeks old) administered 40, 50, 60, or 65 mg/kg/day STZ for 5 consecutive days were 
assessed for non-fasting blood glucose and body weight at Days 0, 7, 10, and 14. (A) Treatment 
with 60 mg/kg/day of STZ (n=10) resulted in significantly increased non-fasting blood glucose 
levels at Day 14 compared to Day 0 and 7 values (*p<0.05 and **p<0.01, respectively). 
Treatment with 40 (n=4), 50 (n=7), or 65 mg/kg/day of STZ (n=13) showed no difference in 
non-fasting blood glucoses levels over time. (B) There were no significant differences in the 
areas under the curve between different concentrations of STZ administered compared to the 
CAB control. (C) Male mice administered 60 mg/kg/day STZ (n=5) had significantly increased 
non-fasting blood glucose levels at Day 14 compared to Day 7 (*p<0.05). There were no 
differences in non-fasting glucose levels for 40 mg/kg/day Males (n=4), 50 mg/kg/day Females 
(n=4), 50 mg/kg/day Males (n=3), 60 mg/kg/day Females (n=5), 65 mg/kg/day Females (n=4), 
and 65 mg/kg/day Males (n=9) over time. (D) There were no significant differences in the areas 
under the curve between each of the treatment concentrations (categorized by sex) compared to 
the CAB control. (E) Mice treated with 50 mg/kg/day, 60 mg/kg/day, or 65 mg/kg/day STZ 
exhibited weight loss (D14/D0) compared to CAB control mice. (F) Treatment with 60 
mg/kg/day of STZ resulted in the highest proportion (30%) of mice with non-fasting blood 
glucose ≥ 15 mmol/l at Day 14. Data represent mean ± standard error of the mean (SEM) for 
A.U.C. graphs and mean ± SD for all remaining data. Non-fasting blood glucose curves were 
compared using a repeated measures two-way ANOVA followed by Tukey’s multiple 
comparison test. Areas under blood glucose curves and changes in body weight were compared 
using a one-way ANOVA followed by Tukey’s multiple comparison test (*p<0.05, **p<0.01, 
***p<0.001). 
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2.3.8 STZ treatment reduced β-cell mass and islet number in CK19-
CreERT;Ai9(RCL-tdT) mice 
While STZ treatment seemed to modestly induce hyperglycemia in CK19-CreERT;Ai9(RCL-tdT) 
mice, histological analysis of the pancreas gives a better indication of β-cell death. CK19-
CreERT;Ai9(RCL-tdT) mice treated with 40, 50, 60, or 65 mg/kg/day (Days 1-5) of STZ exhibited 
decreased β-cell mass and islet number (per mm2) at Day 14 compared to mice that did not receive 
STZ (Figure 2.12 F, G). Additionally, treatment with 60 mg/kg/day of STZ resulted in significantly 
fewer islets per mm2 compared to treatment with 50 mg/kg/day. STZ treatment did not affect islet 
circumference compared to control mice (Figure 2.12 H). Based on the effects of 60 mg/kg/day 
STZ treatment on non-fasting blood glucose and β-cell mass, we decided this dose would be 
optimal for administration in CK19-CreERT;Ai9(RCL-tdT) mice prior to hMSC CM iPan 
injection. 
 
2.3.9 Glucose tolerance was impaired in STZ-treated CK19-
CreERT;Ai9(RCL-tdT) mice 
Based on the collective effects of STZ treatment on non-fasting blood glucose, β-cell mass, and 
islet density, we chose 60 mg/kg/day as our optimal dose. A glucose tolerance test gives a better 
indication of real-time β-cell function in controlling blood glucose. CK19-CreERT;Ai9(RCL-tdT) 
mice treated with 60 mg/kg/day of STZ (Days 1-5) and CAB control mice were fasted for 3 hours 
on Day 14 before receiving bolus glucose (2 mg/kg) by i.p. injection. Blood glucose was assessed 
at 0, 5, 10, 15, 30, 45, 60, 90, and 120 minutes. STZ-treated mice demonstrated significantly 
increased blood glucose levels 120 minutes after bolus injection compared to CAB control mice 
(Figure 2.13A). STZ treated mice had significantly increased A.U.C. for blood glucose compared 
to CAB control mice, indicating impaired glucose tolerance (Figure 2.13B). 
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Figure 142.12 STZ treatment in CK19-Cre-ERT;Ai9(RCL-tdT) mice decreased β-cell mass and islet number. 
Figure 2.12 STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice decreased β-cell mass and 
islet number. CK19-CreERT;Ai9(RCL-tdT) mice (8-12 weeks old) were treated with 40 (n=4), 
50 (n=7), 60 (n=10), or 65 (n=13) mg/kg/day of STZ by i.p. injection (Days 1-5). (A-E) 
Representative photomicrographs of frozen pancreas sections at Day 14 are shown. STZ treatment 
resulted in significantly decreased (F) β-cell mass and (G) number of islets per mm2 compared to 
no STZ control mice. Treatment with 60 mg/kg/day resulted in significantly fewer islets per mm2 
compared to treatment with 50 mg/kg/day. (H) STZ treatment did not affect islet circumference 
compared to no STZ control mice. Data represent mean ± SD compared using a one-way ANOVA 
followed by Tukey’s multiple comparison test (**p<0.01, ***p<0.001). 
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Figure 152.13 Glucose tolerance was impaired in STZ-treated CK19-CreERT;Ai9(RCL-tdT) mice. 
Figure 2.13 Glucose tolerance was impaired in STZ-treated CK19-CreERT;Ai9(RCL-tdT) 
mice. CK19-CreERT;Ai9(RCL-tdT) (8-12 weeks old) were treated with 60 mg/kg/day of STZ 
(n=7) or CAB (n=4) for 5 consecutive days. On Day 14, mice were fasted for 3 hours before 
receiving bolus glucose (2 mg/kg) by i.p. injection and blood glucose was assessed at 0, 5, 10, 15, 
30, 45, 60, 90, and 120 minutes. (A) STZ-treated mice had significantly increase blood glucose 
levels 120 minutes after bolus injection compared to mice injected with CAB. (B) STZ-treated 
mice demonstrated impaired glucose tolerance compared to mice injected with CAB. Data 
represent mean ± SD compared using a two-way ANOVA followed by Tukey’s multiple 
comparison test for the glucose tolerance time course. A.U.C. data represents mean ± SEM 
compared using a student’s t-test to compare area under the curve (*p<0.05). 
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2.3.10 tdTomato labels CK19-expressing cells in the pancreas of CK19-
CreERT;Ai9(RCL-tdT) mice following tamoxifen administration 
To assess whether this model specifically labels CK19+ cells and quantify labeling efficiency, 
CK19-CreERT;Ai9(RCL-tdT) mice were administered 6 mg tamoxifen by oral gavage 7 days 
before 60 mg/kg/day STZ treatment by i.p. injection for 5 consecutive days. Mouse pancreata were 
harvested at Days 0, 1, 7, and 14 and assessed for tdTomato and CK19 expression by flow 
cytometry and fluorescent microscopy. Mice treated with CAB (vehicle control) were euthanized 
on Day 14. Gated based on F.M.O. samples, live tdTomato+ cells labelled CK19-expressing 
pancreas cells at all timepoints in STZ-treated and CAB-treated mice (Figure 2.14A-D). To assess 
tdTomato labelling efficiency within the CK19+ population, live CK19+ cells were assessed for 
tdTomato expression based on the tdTomato FMO. tdTomao expression was observed in 
approximately 20% of CK19-expressing cells at each timepoint (Figure 2.14E-H). Future studies 
to optimize tamoxifen administration may improve CK19+ cell labeling efficiency, as the 
administered dose and repeated injection frequency may increase the efficiency of Cre 
recombinase activation in CK19-expressing cells250. tdTomato expression was not detected 
(<0.001%) when mice were administered corn oil without tamoxifen. 
 
2.3.11 Pancreatic insulin expression diminished following STZ treatment 
in CK19-CreERT;Ai9(RCL-tdT) mice 
While CK19-CreERT;Ai9(RCL-tdT) mice exhibited decreased β-cell mass and impaired glucose 
tolerance following STZ treatment, the proportion of insulin+ cells during STZ treatment is an 
important indicator of the effectiveness of STZ treatment. Mice were treated with 6 mg Tamoxifen 
followed by 7 days of rest. Mice were subsequently treated with 60 mg/kg/day of STZ (Days 1-5). 
At Days 0, 1, 7, and 14, pancreatic insulin expression was assessed by flow cytometry. Non-fasting 
blood glucose at Day 14 was not significantly increased compared to Day 0 (Figure 2.15C). The 
total proportion of insulin-expressing cells within the pancreas was significantly decreased at Days 
7 and 14 compared to Day 0 (Figure 2.14A, D). Insulin expression within tdTomato+ cells was 
significantly reduced at Day 14 compared to Days 0 and 1 (Figure 2.15B,E). 
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Figure 162.14 tdTomato labeled CK19-expressing cells in the pancreas following tamoxifen treatment in CK19-CreERT;Ai9(RCL-
tdT) mice. 
Figure 2.14 tdTomato labeled CK19-expressing cells in the pancreas following tamoxifen 
treatment in CK19-CreERT;Ai9(RCL-tdT) mice. CK19-CreERT;Ai9(RCL-tdT) mice were 
treated with 6 mg Tamoxifen by oral gavage. After 7 days rest, mice were administered 60 
mg/kg/day STZ by i.p. injection for 5 consecutive days. Mouse pancreata were harvested at Days 
0, 1, 7, and 14 and assessed for tdTomato and CK19 expression by flow cytometry (n=4-7) and 
fluorescent microscopy. Mice treated with CAB (vehicle control) instead of STZ were sacrificed 
14 days after the first day of treatment (n=4). (A) Live (Zombie-) tdTomato+ cells were assessed 
for CK19 expression based on the CK19 F.M.O samples. (B) Representative dot plot of CK19 
expression vs. SSC-A (gated on live tdTomato+ cells). (C) Representative photomicrograph of 
tdTomato and CK19 expression. (D) tdTomato labelled CK19-expressing pancreatic ductal cells 
at all timepoints in STZ-treated and CAB mice. To assess tdTomato labelling efficiency within the 
CK19+ ductal population, live CK19+ cells were assessed for tdTomato expression based on the 
(E) tdTomato FMO. (F) Representative dot plot showing tdTomato expression in live CK19+ cells. 
(G) Representative photomicrograph showing CK19 and tdTomato expression in a duct. (H) 
tdTomato expression was observed in approximately 20% of CK19+ ductal cells at each timepoint. 
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Figure 172.15 STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice decreased the proportion of insulin-expressing cells within the 
pancreas. 
Figure 2.15 STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice decreased the proportion 
of insulin-expressing cells within the pancreas. CK19-CreERT;Ai9(RCL-tdT) mice were treated 
with 6 mg Tamoxifen by oral gavage. After 7 days rest, mice were treated with 60 mg/kg/day STZ 
by i.p. injection for 5 consecutive days. At Days 0, 1, 7, and 14, pancreatic insulin expression was 
assessed by flow cytometry (n=4-7). (A) Representative dot plots for insulin vs. SSC-A (gated on 
live cells) at each timepoint and CAB control mice are shown. (B) Representative dot plots for 
insulin vs. SSC-A (gated on live tdTomato+ cells) at each timepoint and CAB control mice are 
shown. (C) Non-fasting blood glucose at Day 14 was not significantly different compared to Day 
0. (D) Insulin-expressing β-cells at Days 7 and 14 were significantly decreased compared to Day 
0. (E) Within tdTomato+ cells, the proportion of insulin+ β-cells was significantly decreased at 
Day 14 compared to Days 0 and 1. Data represent mean ± SD compared using a one-way ANOVA 
followed by Tukey’s multiple comparison test (*p<0.05, **p<0.01). 
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2.3.12 STZ treatment increased the proportion of infiltrating CD45+ cells 
in the pancreas of CK19-CreERT;Ai9(RCL-tdT) mice 
To further investigate whether leukocyte infiltration plays a role in STZ-mediated injury, pancreata 
from CK19-CreERT;Ai9(RCL-tdT) mice treated with Tamoxifen 7 days before STZ treatment 
(Days 1-5) were assessed for CD45 expression, a pan-leukocyte marker251,252, by flow cytometry. 
The proportion of CD45+ cells in the pancreas was significantly increased at Days 1 and 7 
compared to Day 0 (Figure 2.16A,D). Within CK19+ cells, the proportion of CD45+ cells was 
significantly increased at Day 7 compared to Days 0 and 14 (Figure 2.15B,E). Within the 
tdTomato+ cell population, the proportion of CD45+ cells was significantly increased at Day 7 
compared to Day 0 (Figure 2.16C,F). 
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Figure 182.16 STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice increased the proportion of CD45+ cells in the pancreas. 
Figure 2.16 STZ treatment in CK19-CreERT;Ai9(RCL-tdT) mice increased the proportion 
of CD45+ cells in the pancreas. CK19-CreERT;Ai9(RCL-tdT) mice were treated with 6 mg 
Tamoxifen by oral gavage. After 7 days rest, mice were treated with 60 mg/kg/day STZ for 5 days. 
At 0, 1, 7, and 14 after STZ treatment, pancreatic CD45 expression was assessed by flow cytometry 
(n=4-7). (A) Representative dot plots for CD45 vs. SSC-A (gated on live cells) at each timepoint 
and for CAB control mice are shown. (B) Representative dot plots for CD45 vs SSC-A (gated on 
live CK19+ cells) at each timepoint and for CAB control mice are shown. (C) Representative dot 
plots for CD45 vs. SSC-A (gated on live tdTomato+ cells) at each time point and for CAB control 
mice are shown. (D) CD45+ leukocytes within the pancreas were significantly increased at Days 
1 and 7 compared to Day 0. (E) Within CK19+ ductal cells, the proportion of CD45+ leukocytes 
was significantly increased at Day 7 compared to Days 0 and 14. (F) Within tdTomato+ cells, the 
proportion of CD45+ cells was significantly increased at Day 7 compared to Day 0. Data represent 
mean ± SD compared using a one-way ANOVA followed by Tukey’s multiple comparison test 
(*p<0.05, ***p<0.001). 
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2.4 Discussion 
 These studies demonstrated that hMSC CM increased CK19+ cell proliferation in vitro and 
characterized a lineage tracing mouse model to follow CK19+ cell fate following STZ-induced β-
cell ablation followed by hMSC CM intrapancreatic injection in hyperglycemic mice. We utilized 
DBA lectin expression followed by serum supplemented culture as methodology to purify and 
culture viable cells enriched for CK19 expression231. hMSC CM supplementation increased 
proliferation rates of CK19-expressing cells in vitro, although indication of mesenchymal or 
endocrine phenotype transition were not observed. We also characterized a lineage tracing mouse 
model that labels CK19-expressing cells in the pancreas following tamoxifen administration. Low-
dose STZ treatment for 5 days induced hyperglycemia and diminished the insulin+ population 
within the pancreas. Collectively, these data suggest that hMSC CM positively impacts the growth 
kinetics of CK19-expressing cells in vitro and that CK19-CreERT;Ai9(RCL-tdT) mice may be 
used in future experiments to assess the contribution of CK19-expressing cells during islet 
regeneration following hMSC CM intrapancreatic injection in hyperglycemic mice. 
 
While DBA lectin+ cells exhibited ~40% CK19 expression as assessed by flow cytometry, 
subsequent culture in complete PDC media further enriched for CK19 expression within this 
population (≈ 83% purity). Thus, this purification and culture process represents a reliable 
methodology to culture viable mouse pancreatic cells enriched for CK19 expression. hMSC CM 
supplementation into the culture media of DBA lectin+ cells isolated from healthy mice increased 
their proliferative response at 2 days, but no difference was observed at 5 days. This increase in 
proliferation was not observed in cell cultures from STZ-treated mice. The MSC secretome, 
comprised of soluble factors and extracellular vesicles, contains immunomodulatory, anti-
apoptotic, pro-angiogenic, proliferative, and growth factors that facilitate tissue repair187,190–192. 
hMSC CM has previously been shown to improve viability and migratory capacity of a human 
proximal tubular epithelial cell line following toxic chemical exposure, showcasing its protective 
effects on cells exposed to harsh environments including chemical treatment and cell culture 
assays253. Protective effects of hMSC CM, including enhanced survival, proliferation, or 
immunodulatory effects, has also been observed in endothelial cell, synovial explant, and 
microglia cultures254–256. Interestingly, cultured CK19+ cells isolated from healthy mice exhibited 
higher rates of proliferation compared to cells isolated from STZ-treated mice. While the effects 
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of STZ treatment on pancreatic β-cells have been well characterized, phenotypic and functional 
changes in non-endocrine pancreatic cells, including the duct and acinar cells, and the ability of 
STZ to indirectly impact islet regeneration following β-cell destruction has not been reported. 
Further characterization of these phenotypic changes on non-endocrine cell populations, such as 
the expression of cell cycle regulators or EMT markers, could reveal additional cellular targets 
that contribute to pancreatic repair in hyperglycemic mice.  
 
Mesenchymal or endocrine phenotype transition was not observed in cultures of DBA 
lectin+ cells from healthy or STZ-treated mice after 2, 4, or 7 days of cultured with hMSC CM. 
Further evaluation of phenotypic changes should be conducted in a 3-dimensional culture 
environment (e.g. cells suspended in collagen spheres) and transcriptome analysis of cell cycle, 
mesenchymal, and endocrine cell regulators should be investigated. Evidence for MSC CM 
modulation of differentiation following culture supplementation has been reported. hMSC CM has 
previously been shown to enhance chondrogenic, osteogenic, and hematopoietic differentiation in 
hESC cultures257,258. Culture supplementation with MSC CM also upregulated expression of 
cardiomyocyte-related genes in cardiac progenitor cells259. 
 
To evaluate the contribution of CK19-expressing cells in hMSC CM induced islet 
regeneration, we first aimed to develop and characterize a model to follow the fate of CK19-
expressing cells within the pancreas. We used CK19-CreERT;Ai9(RCL-tdT) mice, which utilize 
tamoxifen pulse-chase labelling of CK19+ cells221,222. A single tamoxifen treatment (6 mg) was 
sufficient to induce specific labelling of CK19-expressing cells in the pancreas one-week post-
administration. Absence of tdTomato detection following corn oil vehicle control administration 
indicated that the CK19-CreERT promoter was not leaky. tdTomato labelling efficiency of CK19+ 
cells was approximately 20% across time. Further optimization of tamoxifen dosage (e.g. multiple 
administrations) may increase labeling efficiency. tdTomato labelling and promoter leakiness 
should also be assessed over a long-term period (e.g. 42 days) when characterizing hMSC CM-
induced islet regeneration in these mice. 
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As CK19-CreERT;Ai9(RCL-tdT) mice possess active DNA-dependent protein kinase 
(DNA-PK), a DNA repair enzyme which is truncated and inactive in NOD/SCID mice260,261, we 
hypothesized that a higher STZ dose would be required to induce hyperglycemia and loss of β-cell 
mass compared to the 35 mg/kg/day administered to NOD/SCID mice, as greater STZ sensitivity 
has been reported in NOD/SCID mice which lack functional T-cells262. Consistent induction of 
severe hyperglycemia was difficult to achieve in CK19-CreERT;Ai9(RCL-tdT) mice. Treatment 
with 60 mg/kg/day for 5 consecutive days caused the greatest proportion of mice to become 
hyperglycemic (≥15 mmol/l non-fasting blood glucose) by Day 14. These mice exhibited 
decreased β-cell mass and islet density with no change in islet circumference, compared to control 
mice, and demonstrated impaired glucose tolerance following glucose bolus injection. Similarly, 
pancreatic biopsies from patients with T1D exhibit decreased islet density, while islet size was 
maintained compared to healthy subjects263. While there were some mice who did not become 
hyperglycemic, those considered suitable for hMSC CM injection will have non-fasting blood 
glucose levels between 15 and 25 mmol/l at Day 14. 
Along with pancreatic β-cell loss, insulin+ cells within the pancreas were significantly 
decreased at Days 7 and 14. Similarly, within the tdTomato+ cell population, the frequency of 
insulin+ cells was diminished over time and were rare at Day 14 (<0.5%). This indicates that STZ 
treatment was successful in mediating β-cell destruction, and that emergence of insulin-expressing 
tdTomato+ cells following hMSC CM iPan injection, if absent in vehicle control mice, could truly 
be attributed to the regenerative microenvironment of the hMSC secretome in future experiments. 
Additionally, STZ treatment induced leukocyte infiltration in mice. While NOD/SCID 
mice treated with 35 mg/kg/day STZ demonstrated a stable proportion of CD45+ cells within the 
pancreas, F4/80 upregulation at Day 10 indicated macrophage differentiation in response to 
increased β-cell apoptosis. Within CK19+ cells, an increase in F4/80+ cells on the last day of STZ 
treatment (Day 5) may indicate macrophage infiltration in response to pancreatic injury. Treatment 
of CK19-CreERT;Ai9(RCL-tdT) mice with 60 mg/kg/day of STZ induced pancreatic infiltration 
of CD45+ cells at Days 1 and 7. Within CK19+ and tdTomato+ cells, CD45+ leukocyte infiltration 
at Day 7 was observed, indicating possible interactions between leukocytes and pancreatic 
epithelial cells in response to STZ treatment. Future studies investigating leukocyte subpopulation 
breakdowns (e.g. macrophages, T-cells) during STZ-induced CD45+ cell infiltration will provide 
65 
 
 
insight into cellular phenotypes mediating the immune response. Macrophage and T-cell islet 
infiltration and subsequent release of inflammatory cytokines, including IL-1β, IFN-γ, and TNF-
α, mark key steps in diabetes pathogenesis resulting in β-cell destruction22,56–61. Macrophages play 
a crucial role in tissue repair in response to injury or stress. During inflammation, macrophages 
secrete chemotactic factors to recruit immune cells and clear cellular debris from apoptotic cells 
via phagocytosis264. Evidence for pancreatic macrophage infiltration following STZ treatment has 
been reported265–267. While macrophages normally play an anti-inflammatory role in tissue repair, 
phagocytosis of apoptotic β-cells and elevated blood glucose levels promote a proinflammatory 
macrophage phenotype, potentially tipping the balance to favour β-cell destruction over 
regeneration268,269. T-cell dependent Class II MHC antigen expression and subsequent pancreatic 
T-cell infiltration has been demonstrated in mice following multiple low dose STZ treatment270,271. 
Infiltrating T-cells increase INF-γ release, further mediating inflammation and destruction within 
the pancreas271. Thus, macrophages and T-cells represent key targets in attenuating inflammation 
and destruction in response to β-cell injury, and their regulation may play an important role in 
developing a regenerative microenvironment to promote islet regeneration. 
In summary, these studies show increased proliferation of hMSC CM supplemented murine 
ductal cells in vitro and provide proof-of-concept characterization of CK19-CreERT;Ai9(RCL-
tdT) mice during STZ treatment in vivo. The CK19-CreERT;Ai9(RCL-tdT) mouse model 
represents a valuable tool that required characterization prior to use in future studies to follow the 
fate of CK19-expressing cells during hMSC CM induced islet regeneration. Future studies, 
including optimization of tamoxifen treatment and in-depth characterization of pancreatic 
leukocyte infiltration in response to STZ treatment, will further solidify CK19-CreERT;Ai9(RCL-
tdT) mice as a sound model for CK19+ cell lineage tracing and identify additional potential cellular 
targets to maximize islet regeneration, respectively. These studies ultimately aid in developing a 
cell-free regenerative therapy to stimulate islet regeneration to treat patients with diabetes. 
 
 
 
 
66 
 
 
 
 
 
 
 
 
 
 
3.0 Discussion 
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3.1 Summary 
 The primary objective of this research was to determine the effects of hMSC CM on murine 
ductal cells in vitro and to characterize a lineage tracing mouse model for the future assessment of 
CK19-expressing cell contribution to hMSC CM stimulated islet regeneration in vivo. We have 
previously shown that iPan injection of Wnt+ hMSC CM reliably reduces systemic blood glucose 
and rescues β-cell mass in hyperglycemic mice by stimulating the formation of small ductal-
associated islet clusters via paracrine signals in mice with STZ-mediated β-cell ablation198–200,207. 
Bone marrow-derived hMSC (P4, 80% confluent) were cultured in serum-free media for 24h to 
generate Untreated, Wnt+, or Wnt- CM using pharmacological small molecule treatment. CK19+ 
cells from mouse pancreata, purified by DBA lectin+ FACS were cultured in basal DMEM/F-12 
media supplemented with hMSC CM. CK19+ cells from healthy mice exhibited increased 
proliferation at 2 days in culture with either Untreated, Wnt+, or Wnt- hMSC CM compared to 
basal media alone. Although proliferation was diminished at 5 days after hMSC CM 
supplementation, we found that hMSC CM, irrespective of Wnt-pathway stimulation, secreted 
regenerative stimuli that support short-term proliferation of CK19+ cells in vitro. Notably, CK19+ 
cells isolated from STZ-treated mice did not exhibit increased proliferation compared to basal 
DMEM/F-12 at 2 or 5 days of culture. Indeed, CK19+ cells isolated from STZ-treated mouse 
pancreata exhibited less proliferation in culture compared to cells from healthy mice, suggesting 
STZ treatment changes CK19+ cell growth rates in subsequent culture. Finally, evidence of 
epithelial-to-mesenchymal transition and endocrine phenotype acquisition were not observed in 
hMSC CM supplemented cultures with or without STZ treatment. 
 
 Next, characterization of CK19-CreERT;Ai9(RCL-tdT) lineage tracing mice was 
conducted. A single dose of tamoxifen (6 mg) induced specific labeling (tdTomato+) of CK19+ 
cells within the pancreas. The labelling efficiency of CK19+ cells with tdTomato was 
approximately 20%. Low dose STZ treatment (60 mg/kg/day) for 5 consecutive days induced 
hyperglycemia by Day 14 and insulin+ cells within the pancreas were also diminished at Day 14, 
with a corresponding decrease in β-cell mass. Reduced islet density was observed, while average 
islet circumference remained unchanged after STZ treatment. STZ treatment also stimulated 
pancreatic infiltration of leukocytes, which was also reflected within the CK19+ and tdTomato+ 
cell populations as there was a higher proportion of CD45+ cells. This may indicate immune cell 
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targeting of these populations as an indirect consequence of STZ treatment. Similarly, treatment 
of NOD/SCID mice with low dose STZ (35 mg/kg/day for 5 consecutive days) also resulted in 
macrophage (F4/80+) infiltration into the pancreas. Collectively, these findings suggest that 
CK19-CreERT;Ai9(RCL-tdT) mice represent a suitable model to characterize CK19+ cell 
contribution to islet regeneration following iPan injection of hMSC CM in STZ-treated mice. 
 
3.2 hMSC CM improved proliferation of murine CK19+ cell in vitro, 
irrespective of Wnt-pathway stimulation or inhibition 
 As observed by Kuljanin et al.208, treatment of hMSC with CHIR99021 (≥ 10 μM) 
increased intracellular β-catenin levels without impacting hMSC viability, indicating Wnt-
pathway stimulation was achieved. However, hMSC treatment with IWR-1 did not reduce 
intracellular β-catenin levels, contrary to previous observations using exclusively regenerative 
hMSC samples208. Low baseline levels of β-catenin/Wnt-pathway signaling in these non-
regenerative hMSC samples may possibly contribute to this lack of observed downregulation and 
suggests that the Wnt-pathway was not active in all cultured hMSC samples. 
 
 Isolation of DBA lectin+ cells from mouse pancreata, followed by culture in complete PDC 
media proved effective in purifying viable CK19+ cells (~83% CK19+/DAPI+). As CK19 is an 
intracellular marker requiring antibody labeling, cells must be fixed and permeabilized to visualize 
or isolate CK19+ cells. As a surrogate marker for viable CK19+ ductal epithelial cells240,272, DBA 
lectin, which specifically labels the α-linked N-acetylgalactosamine carbohydrate moiety, enriched 
2-fold for viable CK19+ cells233. Further purification was achieved by culturing DBA lectin+ cells 
in complete PDC media as outlined by Reichert et al231. While supplementation of DBA lectin+ 
cells with hMSC CM, irrespective of Wnt-pathway stimulation or inhibition, improved 
proliferation of CK19+ cells at Day 2 compared to basal DMEM/F-12, this proliferative effect was 
diminished at Day 5. hMSC CM supplementation of DBA lectin+ cells isolated from STZ treated 
mice did not significantly change CK19+ cell proliferative frequencies. hMSC CM contains a 
combination of secreted factors and extracellular vesicles that commonly exhibit proliferative, pro-
survival, and immunomodulatory effects to facilitate tissue repair187,190–192. Previous studies have 
shown that the hMSC secreted factors, such as PDGF-β, IL-6, Erk1/2 pathway activators, VEGF, 
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and monocyte chemotactic protein 1, can contribute to enhanced proliferation in co-culture with 
multiple cell types273–275. hMSC CM supplementation can increase survival and  proliferation in 
endothelial cell, synovial explant, and microglia cell cultures254–256. hMSC CM supplementation 
has also been reported to improve culture efficiency of epithelial cells from the human proximal 
tubule and increased cell viability and migratory capacity following toxic chemical exposure253. 
Interestingly, pancreatic ductal cell proliferation rate is increased in obese individuals and in 
patients with T2D 10-fold and 4-fold, respectively276. Based on our previous observations of 
increased islet/ductal association after intrapancreatic hMSC CM injection207, this compensatory 
proliferative mechanism, stimulated by the presence of regenerative effectors, may contribute to 
murine islet regeneration in situ.  Interestingly, CK19+ cells isolated from STZ-treated mouse 
pancreata exhibited less proliferation compared to cells from healthy mice across conditions. 
While the effects of STZ treatment on pancreatic β-cells have been well characterized, phenotypic 
and functional changes in nearby pancreatic cells, including the duct and acinar cells, and the 
ability of STZ to indirectly impact islet regeneration following β-cell destruction has not been 
reported. Further characterization of these phenotypic changes on non-endocrine cell populations, 
such as the expression of cell cycle regulators or EMT markers, could reveal additional cellular 
targets that contribute to pancreatic repair in hyperglycemic mice. 
 
 Studies conducted by the Collombat and Bonner-Weir groups suggest that islet 
regeneration involves EMT of duct-associated facultative progenitors followed by α- then β-cell 
endocrine transition18,19,148,153,154,156,160,277,278. To investigate whether hMSC CM could stimulate 
phenotype transition of murine CK19+ cells in vitro, we looked for evidence of vimentin or 
glucagon/insulin expression during short-term cell culture. CK19 and vimentin co-localization was 
not observed 2, 4, or 7 days after hMSC CM supplementation. Additionally, CK19+ cells with 
glucagon or insulin co-localization was also not observed at each timepoint. Further evaluation of 
phenotypic changes should be conducted in a 3-dimensional culture environment (e.g. cells 
suspended in collagen spheres), which more closely mimics native tissue metabolic responses279. 
Transcriptome analyses of cell cycle, mesenchymal, and endocrine cell regulators should also be 
investigated in future studies. Evidence of hMSC CM-directed differentiation has been previously 
observed. hMSC CM has been shown to enhance differentiation of undifferentiated hESC into 
chondrogenic, osteogenic, and hematopoietic lineages257,258. Evidence of enhanced cardiac 
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progenitor cell differentiation into cardiomyocytes based on upregulation of lineage-specific genes 
has also been reported259. Additionally, further investigation into hMSC-mediated improvement 
of functional outcomes in models of central nervous system injury through trophic effects revealed 
that hMSC culture supplementation selectively promoted neuronal stem cell differentiation into 
neurons and oligodendrocytes280. Thus, enhanced differentiation of a putative, pancreas-derived, 
facultative stem cell population in vivo following tissue injury seems plausible given regenerative 
signals provided by hMSC CM. While we have previously shown that Wnt+ hMSC CM reliably 
rescues hyperglycemia and β-cell mass following STZ-mediated ablation, the contribution of β-
cell proliferation alone could not explain this robust improvement, while neoislet budding from 
pancreatic ducts seemed common207. Given this evidence, it is plausible that hMSC CM may 
stimulate differentiation of facultative progenitors within the pancreas, and cells within the ducts 
(CK19+) represent a strong candidate. While differentiation of CK19+ cells into endocrine cells 
was not observed in vitro following hMSC CM supplementation, evaluation of their contribution 
to islet regeneration in their native tissue environment in vivo will provide deeper insight into 
whether this population represents a cell responsive to hMSC secreted signals. 
 
3.3 CK19-CreERT;Ai9(RCL-tdT) mice represent a strong model to 
characterize CK19+ cell contribution to islet regeneration 
 Lineage tracing mouse models which use lineage-specific promoters can label and permit 
long-term fate tracking even if phenotype transition or differentiation occurs. We used the CK19-
CreERT;Ai9(RCL-tdT) mouse model to label CK19-expressing cells following tamoxifen 
administration. First described by Means et al., the tamoxifen-inducible Cre-ERT was knocked 
into the CK19 locus221. Tamoxifen administration in postnatal mice induced labeling in a wide 
array of epithelial populations, including pancreatic ducts, hepatic ducts, stomach, and intestinal 
cells221. The reporter Ai9(RCL-tdT) mouse line has shown strong native fluorescence when 
crossed with different Cre lines222. Thus, we bred CK19-CreERT mice with Ai9(RCL-tdT) 
reporter mice to generate a mouse line that would label CK19+ cells with bright tdTomato 
fluorescence following tamoxifen administration. Single dose (6 mg p.o.) tamoxifen treatment 
induced labeling in CK19+ cells within the pancreas at one-week post-administration. Of the 
tdTomato+ cells, >90% were CK19+ by flow cytometry, indicating strong CK19-labeling 
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specificity. Administration of corn oil vehicle control (no tamoxifen) resulted in < 0.001% 
tdTomato+ cell detection, indicating that this Cre recombinase system was not leaky. Of the 
CK19+ cells detected, only 20% were tdTomato+ after a single injection of tamoxifen. Future 
studies to optimize tamoxifen administration may improve CK19+ cell labeling efficiency, as the 
administered dose and repeated injection frequency may increase the efficiency of Cre 
recombinase activation in CK19-expressing cells250. Higher tamoxifen dose, or multiple low doses, 
should maximize labeling in future studies and should permit localization of labelled cells during 
hMSC CM neoislet formation281,282. Whether the CK19+ cell population directly contributes to 
neoislet formation or indirectly facilitates neoislet budding from an alternative lineage, labeling 
studies using this mouse model should be performed to determine the origins of islet regeneration. 
However, tamoxifen toxicity represents a challenge in lineage tracing models. High doses of 
tamoxifen have been shown to cause gastric epithelium and liver damage283,284. Thus, the optimal 
tamoxifen dose should be that which induces maximal Cre activation without injury to the mice. 
Future studies are underway to determine this optimal dose. Additionally, as single-cell 
transcriptome analysis has suggested heterogeneity within the pancreatic ductal cell population, 
further investigation into differential expression of ductal cell markers, including CK19, within 
the tamoxifen labeled population would clarify the presence of a potential progenitor population149. 
 
Another aspect of the model we needed to assess prior to inducing hMSC CM mediated 
islet regeneration was hyperglycemia induction after STZ treatment. Previously, we have shown 
that administration of low dose STZ (35 mg/kg/day) for 5 consecutive days results in 
hyperglycemia (non-fasting blood glucose 15-25 mmol/l) and impaired glucose tolerance at Day 
10 in NOD/SCID mice198–200,207,225,226. Thus, we used a similar strategy administering STZ to 
C57BL/6 CK19-CreERT;Ai9(RCL-tdT) mice. Because CK19-CreERT;Ai9(RCL-tdT) mice are 
immunocompetent and contain intact of DNA-PK, a DNA repair enzyme that confers the SCID 
phenotype when inactivated260,261, we hypothesized that a higher STZ dose would be required to 
induce hyperglycemia, as greater STZ sensitivity has been reported in NOD/SCID mice262. We 
found that 60 mg/kg/day STZ treatment for 5 days induced hyperglycemia and impaired glucose 
tolerance in 1/3 to 1/2 of the mice at Day 14. CAB control mice exhibited normoglycemia and 
normal glucose tolerance at Day 14. While not all the mice were hyperglycemic at Day 14, only 
mice that have non-fasting blood glucose values between 15 and 25 mmol/l will be used for hMSC 
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CM transplantation studies. Mice that received STZ treatment had decreased β-cell mass and islet 
density, while islet circumference remained unchanged. 
 
 Following with the trends seen in decreasing β-cell mass, the proportion of insulin+ cells 
in the pancreas decreased with time during the STZ treatment protocol. At Days 7 and 14 following 
the start of STZ treatment, the proportion of insulin+ cells within the pancreas had significantly 
decreased, indicating that the STZ treatment protocol was effective in achieving β-cell ablation.  
Additionally, insulin+ cells within the tdTomato+ cell population decreased with time following 
STZ treatment. Very low detection levels of insulin+ cells at Day 14 means that any observed 
tdTomato+/insulin+ cells following hMSC CM iPan injection, pending emergence of this 
population is not seen in PBS control mice, could be attributed to the islet regenerative effects of 
the hMSC secretome. Based on studies including those from the Collombat and Bonner-Weir 
groups, there has been growing support that ductal cells, or subpopulations within the ductal 
lineage, may serve as a facultative progenitor population to compensate for pancreatic injury or 
disease44,154,156. In order to investigate whether hMSC CM stimulates this reprogramming, lineage 
tracing models, like the CK19-CreERT;Ai9(RCL-tdT) mice described in this study, will need to 
be utilized to assess the relative contributions of various pancreatic cell populations to islet 
regeneration. This study lays the groundwork to identify key pancreatic target populations to 
increase islet regenerative efficiency. 
 
3.4 Leukocyte infiltration plays a role in STZ-mediated pancreatic injury 
Apoptosis of β-cells in diabetes pathogenesis results from T-cell and macrophage islet 
infiltration and subsequent release of inflammatory cytokines, including IL-1β, IFN-γ, and TNF-
α which activate signalling pathways that mediate cell death22,56–61. Macrophage and T-cell 
pancreatic infiltration has also been reported following STZ treatment265–267,270,271. Treatment of 
NOD/SCID mice with low dose STZ resulted in increased F4/80+ macrophage specification within 
pancreatic CD45+ leukocytes. Additionally, treatment of immunocompetent CK19-
CreERT;Ai9(RCL-tdT) mice with low dose STZ (60 mg/kg/day x 5 days) resulted in increased 
CD45+ leukocyte pancreatic infiltration. Macrophages play a crucial role in mediating tissue repair 
in response to injury or stress. While macrophages normally play an anti-inflammatory role to 
facilitate tissue repair following tissue insult, STZ treatment stimulates phagocytosis of apoptotic 
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β-cells, which polarizes macrophages towards a pro-inflammatory phenotype268,269. Similarly, STZ 
stimulates T-cell pancreatic infiltration in immunocompetent mice and inflammatory cytokine 
release271. Chronic inflammation is associated with the onset of diabetes and its 
complications83,285,286. Upregulation of inflammatory cytokines, including IFN-γ, TNF-α, and IL-
1β are associated with increased reactive oxidative species production that play a significant role 
in β-cell apoptosis286. STZ treatment also increased CD45+ cell co-localization with CK19 and 
tdTomato, indicating that these cells may also be affected by the STZ-mediated inflammatory 
response. Further investigation into the specific leukocyte lineages that drive this observed 
infiltration will provide insight into the inflammatory mechanism at play and identify potential 
targets to prevent the progression of diabetic complications. Trials aimed at attenuating pro-
inflammatory immunity, including anti-CD20 antibody287,288, inflammatory cytokine 
antagonist289,290, and anti-inflammatory pharmacological agent291–295 administration have shown 
some success in attenuating β-cell apoptosis and symptoms. Thus, dampening the pro-
inflammatory immune response mediated by macrophages and T-cells may represent a promising 
approach to slow disease progression in diabetes pathogenesis, reduce complications, and create a 
regenerative microenvironment to facilitate tissue repair. 
 
It is well-established that the hMSC secretome exhibits immunomodulatory properties 
which have shown some success in treating immune disorders, including graft versus host 
disease296–298 and models of multiple sclerosis299–302. Immunomodulatory functions of MSC 
include promotion of as anti-inflammatory macrophage phenotype, macrophage homing to the site 
of injury, limiting mast cell degranulation, inhibition of lymphocyte proliferation, decreasing 
lymphocyte pro-inflammatory cytokine synthesis, and increasing lymphocyte anti-inflammatory 
cytokine synthesis180. While we’ve previously shown that Wnt+ hMSC CM injection provides a 
regenerative microenvironment that stimulates islet regeneration in the NOD/SCID mouse, it is 
possible that the immunomodulatory properties secreted by Wnt+ hMSC may also play a role in 
promoting tissue repair over progressive destruction. Further investigation into the hMSC secreted 
contents that mediate immune modulation may provide insight into strategies to prevent disease 
progression following early diagnosis. 
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3.5 Clinical Implications 
 Our data characterizes an immunocompetent lineage tracing mouse model that can be used 
to determine the contribution of CK19+ ductal cells to hMSC CM stimulated islet regeneration. 
hMSC are readily available and can be expanded efficiently in culture. For hMSC CM to be used 
in a clinical setting, production and expansion of hMSC may need to be scaled up to generate an 
appropriate dose. hMSC CM generated in serum-free culture conditions represents a cell-free 
mixture in which individual factors that are essential for islet regeneration can be identified to 
produce a therapy without the need for cellular purification and expansion. As Wnt-stimulation of 
hMSC in culture generates CM that consistently induces reduced hyperglycemia and β-cell rescue, 
we can circumvent the donor-dependent regenerative variability previously observed by 
pharmacological stimulation of the Wnt-pathway. However, since the hMSC secretome contains 
such a wide variety of factors that may be implicated in islet regeneration and immunomodulation, 
identification of individual essential components may prove to be challenging and labour intensive. 
While a single injection into hyperglycemic mice early in disease progression provides long term 
therapeutic effects, translation to a clinical setting may require multiple treatments. Additionally, 
characterization of β-cell regenerative ability in aged mice (>10 months) will provide further 
insight into hMSC CM clinical potential for older patients with diabetes. 
 
 The CK19-CreERT;Ai9(RCL-tdT) mouse model  described in these studies comes from a 
C57BL/6 background strain. Previously, we have demonstrated islet regeneration in NOD/SCID 
mice, which lack functional T- and B-cells, exhibit low natural killer cell activity, and have reduced 
antigen-presenting cell function303. While NOD/SCID mice previously allowed us to transplant 
cells without immune rejection, now that we are using a cell-free agent, we can use an 
immunocompetent mouse model which is more applicable to the clinical setting. The progression 
of both T1D and T2D involves aberrant immune system activation or inflammation, so an 
immunocompetent model to characterize treatment with hMSC CM alongside the associated innate 
and adaptive immune responses is essential if we are looking towards clinical application. 
Apoptosis of β-cells is mediated by islet infiltration by pro-inflammatory macrophages, as well as 
T-cells in the case of T1D, resulting in cytokine release and phagocytosis22,56–61,304,305. 
Nonetheless, characterizing islet regeneration in CK19-CreERT;Ai9(RCL-tdT) mice will provide 
further insight into response to hMSC CM treatment in the presence of functioning immune cells. 
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 Characterization of CK19-CreERT;Ai9(RCL-tdT) mice as a lineage tracing model to 
determine the contribution of CK19+ cells to islet regeneration following hMSC CM injection will 
aid in elucidating the cellular cascade leading to β-cell mass rescue. RNA-seq of human pancreata 
has revealed heterogeneity and intermediate stages within endocrine cell populations, which could 
indicate potential plasticity within the human pancreas149–152. One hypothesis that has gained 
considerable traction in recent years is the presence of a facultative progenitor cell population 
which resides in the ductal tree44,118,153,154,156. Following Pax4-mediated α- to β-cell transition, 
Hnf1β+ duct-lining cells demonstrated transient activation of Neurogenin 3, an endocrine 
progenitor marker, before adopting an α- then β-cell phenotype and function19,154,156. 
Misexpression of Ngn3 in Hnf1β+ cells stimulated reactivation of the endocrine lineage 
specification pathway, resulting in their transition into functional β-like cells in mice154. Lending 
support to duct cell plasticity, 15% of insulin-expression β-cells, which were not associated with 
other islet cells, have been found in or budding from ductules, paralleling β-cell lineage 
specification processes in the developing pancreas162. Thus, characterization of CK19-
CreERT;Ai9(RCL-tdT) mice, which represents a feasible model to study hMSC CM mediated islet 
regeneration, is a considerable step forward in testing this hypothesis and finding the ‘signal-
receiving cell’. 
 
 Our study has some limitations that need to be addressed as we plan for clinical 
translation22,62–66. Firstly, pathophysiology of T1D involves autoantibodies and autoimmune 
destruction of β-cells. However, our model involves chemical ablation of β-cells to induce 
hyperglycemia. Thus, our model does not address the autoimmune aspects of T1D that may 
actively delete regenerating β-cells. Additionally, this model does not address the obesity-induced 
insulin resistance characteristic of T2D, meaning obesity specific inflammatory cytokines and 
metabolites will not be present throughout our proposed studies. STZ treatment of CK19-
CreERT;Ai9(RCL-tdT) mice results in weight loss compared to control mice, which must be 
monitored closely as hyperglycemia progresses. Additionally, while lineage tracing provides us 
with direct fate-mapping of CK19+ cells with negligible leakiness, increasing labeling efficiency 
to maximize the probability of observing duct-to-β-cell transition requires administration higher 
dosages of tamoxifen, which has the potential to cause gastric and liver complications283,284. 
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3.6 Future Directions 
 This study showed that tamoxifen administration to CK19-CreERT;Ai9(RCL-tdT) mice 
specifically labeled CK19+ cells and that low dose STZ treatment can result in hyperglycemia, 
impaired glucose tolerance, and reduced β-cell mass. Our next steps in this investigation are to 
investigate whether hMSC CM can induce islet regeneration in an immunocompetent host to 
determine the contribution of CK19+ cells to neoislets. This protocol will require treatment with 
tamoxifen followed by a rest period, STZ injection (60 mg/kg/day for 5 days), hMSC CM iPan 
injection, blood glucose monitoring, and histological and flow cytometric analysis according to 
the proposed model and timelines outlined in Figure 3.1. Analysis of tdTomato+ cells by histology 
and flow cytometry during the islet regenerative process will be conducted to determine whether 
they have acquired endocrine phenotype and will provide definitive evidence of any possible 
CK19+ cell contribution to neoislets. Co-localization of tdTomato with β-cell markers including 
insulin, MafA, and Nkx6.1 on a single cell level by flow cytometry and confirmation by confocal 
microscopy would provide strong evidence if this event occurred. tdTomato co-localization with 
other pancreatic cell markers, including those for other endocrine cell types (α-cells, somatostatin 
cells, and PP cells), mesenchymal cells (e.g. vimentin), and acinar cells (e.g. elastase) should also 
be assessed to investigate other avenues of pancreatic plasticity. 
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Figure 193.1 Proposed experimental strategy for assessing ductal cell contribution to β-cell regeneration in CK19-CreERT;Ai9(RCL-
tdT) mice. 
Figure 3.1 Proposed experimental strategy for assessing ductal cell contribution to β-cell 
regeneration in CK19-CreERT;Ai9(RCL-tdT) mice. CK19-CreERT;Ai9(RCL-tdT) mice will 
be used to fate map ductal cells following tamoxifen administration (6 mg per os, Day -21). To 
induce hyperglycemia, mice will be treated with STZ (60 mg/kg/day i.p. injection, Days -14 to -
10), and subsequently receive hMSC CM iPan injection (Untreated, Wnt+, or Wnt-) on Day 0.  
Mice will be monitored twice weekly for non-fasted blood glucose concentrations and euthanized 
at Days 0, 7, and 28 (n=6-8) to assess tdTomato+ cell contribution to β-cell regeneration by 
immunohistochemistry on frozen pancreas sections and flow cytometry on dissociated, fixed, and 
permeabilized pancreatic tissue. EdU will be injected i.p. (200 µg/100 µl) 24h prior to euthanasia 
to assess replication of ductal, α-, or β-cells with or without tdTomato labeling. 
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Whether CK19+ cells contribute to islet regeneration or not, we will subsequently assess 
the contribution of other pancreatic cell types. Based on the hypothesis of ductal-to-α-to-β-cell 
transition18,19,44,154,156, we plan to also use the Glucagon-CreERT2 mouse line crossed with 
Ai9(RCL-tdT) reporter mice to map the fate of α-cells during hMSC CM induced β-cell 
regeneration306.  The experimental strategy and timeline will mirror that presented for CK19-
CreERT;Ai9(RCL-tdT) mice. 
 
 While hMSC CM is a more clinically applicable therapeutic option compared to cellular 
therapies, identification of the specific components of the hMSC secretome that mediate islet 
regeneration would provide further translational ability. Identification and optimization of these 
factors and their relative doses will help ensure uniformity and reproducibility as a treatment 
option to improve outcomes for patients with diabetes. To do this, proteomic analysis and RNA 
sequencing can be used to identify key differences between regenerative and non-regenerative 
hMSC CM and these factors can be modulated to determine whether they are essential to stimulate 
islet regeneration. Further understanding of the islet regenerative cascade leading to β-cell mass 
rescue and the key CM components that mediate this process can be used to generate a cell-free 
therapy, in combination with treatments to combat ongoing autoimmunity in the case of T1D or 
harmful metabolites in the case of T2D, to improve outcomes and β-cell functionality in patients 
with diabetes. 
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